

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
**WO 03/074566 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/00**

(74) Agent: **W.P.THOMPSON & CO.**; Coopers Building,  
Church Street, Liverpool, L1 3AB (GB).

(21) International Application Number: PCT/GB03/00885

(22) International Filing Date: 3 March 2003 (03.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/360,229 1 March 2002 (01.03.2002) US

(71) Applicant: **IMMUNOMEDICS, INC.** [US/US]; 300  
American Road, Morris Plains, NJ 07950 (US).

(71) Applicant (*for BB, MG only*): **MCCALL, John, Douglas**  
[GB/GB]; 25 Haddon Drive, Pensby, Wirral, CH61 8TF  
(GB).

(72) Inventors: **GOVINDAN, Serengulam**; 106 Passaic  
Avenue, Summit, NJ 07901 (US). **QU, Zhengxing**; 15  
Sycamore Way, Warren, NJ 07059 (US). **HANSEN,**  
**Hans, J.**; 6014 Angler Drive, Picayune, MS 39466 (US).  
**GOLDENBERG, David, M.**; 330 Pleasant Valley Road,  
Mendham, NJ 07945 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: RS7 ANTIBODIES

(57) **Abstract:** This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.



**WO 03/074566 A2**

## **RS7 ANTIBODIES**

### **1. FIELD OF THE INVENTION**

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7. The invention further relates to humanized RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

### **2. BACKGROUND OF THE INVENTION**

Man-made binding proteins, in particular monoclonal antibodies and engineered antibodies or antibody fragments, have been tested widely and shown to be of value in detection and treatment of various human disorders, including cancers, autoimmune diseases, infectious diseases, inflammatory diseases, and cardiovascular diseases (Filpula and McGuire, Exp. Opin. Ther. Patents (1999) 9: 231-245). For example, antibodies labeled with radioactive isotopes have been tested to visualize tumors after injection to a patient using detectors available in the art. The clinical utility of an antibody or an antibody-derived agent is primarily dependent on its ability to bind to a specific targeted antigen. Selectivity is valuable for delivering a diagnostic or therapeutic agent, such as isotopes, drugs, toxins, cytokines, hormones, growth factors, enzymes, conjugates, radionuclides, or metals, to a target location during the detection and treatment phases of

a human disorder, particularly if the diagnostic or therapeutic agent is toxic to normal tissue in the body.

The potential limitations of antibody systems are discussed in Goldenberg, *The American Journal of Medicine* (1993) 94: 298-299. The important parameters in the detection and treatment techniques are the amount of the injected dose specifically localized at the site(s) where target cells are present and the uptake ratio, i.e. the ratio of the concentration of specifically bound antibody to that of the radioactivity present in surrounding normal tissues. When an antibody is injected into the blood stream, it passes through a number of compartments as it is metabolized and excreted. The antibody must be able to locate and bind to the target cell antigen while passing through the rest of the body. Factors that control antigen targeting include location, size, antigen density, antigen accessibility, cellular composition of pathologic tissue, and the pharmacokinetics of the targeting antibodies. Other factors that specifically affect tumor targeting by antibodies include expression of the target antigens, both in tumor and other tissues, and bone marrow toxicity resulting from the slow blood-clearance of the radiolabeled antibodies. The amount of targeting antibodies accreted by the targeted tumor cells is influenced by the vascularization and barriers to antibody penetration of tumors, as well as intratumoral pressure. Non-specific uptake by non-target organs such as the liver, kidneys or bone-marrow is another potential limitation of the technique, especially for radioimmunotherapy, where irradiation of the bone marrow often causes the dose-limiting toxicity.

One suggested approach, referred to as direct targeting, is a technique designed to target specific antigens with antibodies carrying diagnostic or therapeutic radioisotopes. In the context of tumors, the direct targeting approach utilizes a radiolabeled anti-tumor monospecific antibody that recognizes the target tumor through its antigens. The technique involves injecting the labeled monospecific antibody into the patient and allowing the antibody to localize at the target tumor to obtain diagnostic or therapeutic benefits. The unbound antibody clears the body. This approach can be used to diagnose or treat additional mammalian disorders.

Another suggested solution, referred to as the “Affinity Enhancement System” (AES), is a technique especially designed to overcome deficiencies of tumor targeting by antibodies carrying diagnostic or therapeutic radioisotopes (US-5,256,395 (1993), Barbet et al., *Cancer Biotherapy & Radiopharmaceuticals* (1999) 14: 153-166). The AES utilizes a radiolabeled hapten and an anti-tumor/anti-hapten bispecific binding protein that recognizes both the target tumor and the radioactive hapten. Haptens with higher valency and binding proteins with higher specificity may also be utilized for this procedure. The technique involves injecting the binding protein into the patient and allowing it to localize at the target tumor. After a sufficient amount of time for the unbound binding protein to clear from the blood stream, the radiolabeled hapten is administered. The hapten binds to the antibody-antigen complex located at the site of the target cell to obtain diagnostic or therapeutic benefits. The unbound hapten clears the body. Barbet mentions the possibility that a bivalent hapten may crosslink with a bispecific antibody, when the latter is bound to the tumor surface. As a result, the radiolabeled complex is more stable and stays at the tumor for a longer period of time. This system can be used to diagnose or treat mammalian disorders.

There remains a need in the art for production of multivalent, monospecific binding proteins that are useful in a direct targeting system and for production of multivalent, multispecific binding proteins that are useful in an affinity enhancement system. Specifically, there remains a need for a binding protein that exhibits enhanced uptake at targeted antigens, decreased concentration in the blood, and optimal protection of normal tissues and cells from toxic pharmaceuticals.

### SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a monospecific monoclonal antibody and fragments thereof that recognizes a tumor-associated antigen, defined as epithelial glycoprotein-1 (EGP-1) by the murine MAb RS7-3G11 raised against human non-small-cell lung carcinoma. The RS7 antigen has been designated as EGP-1 (epithelial glycoprotein-1) following the proposal of the 3<sup>rd</sup> International IASLC Workshop on Lung Tumor and Differentiation Antigens. At least one epitope associated with EGP-1 is alternatively referred to as TROP2 in the literature. In a preferred

embodiment, the antibody or antibody fragment of the present invention binds the same epitope as the murine RS7 antibody disclosed by Stein (*infra*) and other earlier studies. Alternatively, the antibody or fragment may bind an epitope distinct from the epitope that the murine RS7 antibody disclosed by Stein binds. In a preferred embodiment, the anti-EGP-1, or anti-TROP2 antibody or fragment thereof is a chimeric, humanized, or fully human RS7 antibody or fragment thereof.

For example, contemplated in the present invention is a humanized antibody or fragment thereof, wherein the complementarity determining regions (CDRs) of the light chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT. Another embodiment of the present invention is a humanized antibody or fragment thereof, wherein the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV. Also preferred, the humanized antibody or fragment thereof comprises the CDRs of a murine RS7 MAb and the framework region (FR) of the light and heavy chain variable regions of a human antibody, wherein the CDRs of the light chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT; and the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV. Still preferred, the humanized antibody or fragment thereof further comprises the FRs of the light and heavy chain constant regions of a human antibody.

In a preferred embodiment, the humanized RS7 antibody or fragment comprises a FR of a light and/or heavy chain that comprises at least one amino acid substituted by an amino acid residue found at a corresponding location in the RS7 murine antibody. For

example, at least one of the substituted amino acids is preferably at a location selected from the group consisting of residue 38, 46, 68 and 91 of the murine heavy chain variable region of figure 3B, and/or at least one of the substituted amino acids is preferably at a location selected from the group consisting of residue 20, 85 and 100 of the murine light chain variable region of figure 3A.

Also described in the present invention is an antibody fusion protein or fragment thereof that comprises at least two anti-EGP-1 MAb or fragments thereof, wherein the MAb or fragments thereof are selected from the anti-EGP-1 MAb or fragments thereof of the present invention. In a related vein, the antibody fusion protein or fragment thereof comprises at least one first anti-EGP-1 MAb or fragment thereof of any of the anti-EGP-1 antibodies of the present invention and at least one second MAb or fragment thereof, other than the anti-EGP antibodies or fragment thereof in the present invention. For example, the second antibody or fragment thereof may be a carcinoma-associated antibody or fragment thereof. Another preferred embodiment is a fusion protein or fragment thereof that comprises two different epitope-binding anti-EGP-1 antibodies or fragments thereof.

It is one object of this invention to provide a multispecific antibody and fragments thereof that recognize more than one epitope on the RS7 antigen or that has affinity for the RS7 antigen and for a hapten molecule. The latter binding protein is useful for pretargeting a target antigen. Accordingly, a method of delivering a diagnostic agent, a therapeutic agent, or a combination thereof to a target, comprising: (i) administering to a subject a multivalent, multispecific MAb, or fragment thereof (ii) waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and (iii) administering to said subject a carrier molecule comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody, is also described.

It is a further object of this invention to provide a method of delivering a diagnostic or therapeutic agent to a targeted disease that expresses EGP-1 antigen. For example, a method of delivering a diagnostic or therapeutic agent, or a combination thereof, to a target comprising (i) providing a composition that comprises an anti-EGP-1

antibody or fragment thereof bound to at least one therapeutic and/or diagnostic agent and (ii) administering to a subject in need thereof said composition, is described.

Preferably, the diagnostic or therapeutic agent is selected from the group consisting of an isotope, drug, toxin, immuno,modulator, hormone, enzyme, growth factor, radionuclide, metal, contrast agent, and detecting agent.

In another embodiment of the present invention, the method for delivering a diagnostic agent, a therapeutic agent, or a combination thereof to a target comprises (i) administering to a subject a multivalent, multispecific antibody or fragment comprising one or more antigen-binding sites having affinity toward an EGP-1 target antigen and one or more hapten binding sites having an affinity toward a hapten molecule, (ii) waiting a sufficient amount of time for an amount of the non-binding antibody or fragment to clear a subject's blood stream, and (iii) administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof.

Another object of the present invention to provide a cancer cell targeting diagnostic or therapeutic conjugate that comprises an anti-EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of antibodies of the present invention and wherein the anti-EGP-1 antibody or fragment thereof is bound to at least one diagnostic or therapeutic agent. A suitable therapeutic agent is a drug that possesses the pharmaceutical property selected from the group consisting of an antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkylating antibiotic, and combinations thereof. Also preferred is a therapeutic agent selected from the group consisting of a nitrogen mustard, ethylenimine derivative, alkyl sulfonate, nitrosurea, trazene, folic acid analog, anthracycline, taxane, COX-2 inhibitor, tyrosine kinase inhibitor, pyrimidine analog, purine analog, antibiotic, enzyme, epipodophyllotoxin, platinum coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocortical suppressant, antagonist, endostatin taxol, camptothecins, doxorubicin, doxorubicin analog, and a combination thereof. Preferably, the diagnostic agent is selected from the group consisting of a photoactive radionuclide, preferably between 25 and 4000 keV, and a contrast agent.

In a preferred embodiment, a DNA sequence comprising a nucleic acid encoding a MAb or fragment that contains a anti-EGP-1 MAb or fragment thereof of the present invention; an antibody fusion protein or fragment thereof containing at least two of said MAbs or fragments thereof; an antibody fusion protein or fragment thereof containing at least one first anti-EGP-1 MAb or fragment thereof containing the MAb or fragment thereof of the anti-EGP-1 antibodies and fragments of the present invention and at least one second MAb or fragment thereof, other than the anti-EGP-1 MAb or fragment thereof described herein; or an antibody fusion protein or fragment thereof comprising at least one first MAb or fragment thereof comprising said MAb or fragment thereof of any of the antibodies described herein and at least one second MAb or fragment thereof, other than the MAb or fragment thereof of any one of the antibodies described herein, wherein the second MAb is reactive with an antigen selected from the group consisting of EGP-2, MUC 1-4, A33, CSAp, CEA, Le(y), Tn, Tag-72, PSMA, PSA, EGFR, HER2/neu, AFP, HCG, HCG-beta, ferritin, PAP, PLAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, PAM4-antigen, oncogene products, or a combination thereof. The second MAb may instead be reactive with vascular endothelial antigens associated with tumors, such as VEGF (vascular endothelial growth factor) and PlGF (placenta growth factor). Selection of the second antibody is dependent on tumor cell type. For example, anti-PSMA or anti-PSA antibodies may be used for treating or diagnosing prostate cancer, anti-CEA or anti-MUC1, MUC2, MUC3 and MUC4 antibodies for breast, ovarian, lung, and colon cancer, EGFR for colon and head and neck cancers, anti-CSAp antibodies for colon and ovarian cancer, and anti-HER/neu for breast, ovarian and other cancers. These are merely given as examples, and are not intended to be limiting. Expression vectors and host cells containing this DNA sequence are also preferred embodiments of the present invention.

Also provided herein are methods for diagnosing and treating a malignancy. For example, a method for diagnosing or treating cancer, comprises (i) administering to a subject in need thereof amultivalent, multispecific antibody or fragment comprising one or more antigen-binding sites having affinity toward an EGP-1 traget antigen and one or more hapten bidning sites having an affinity toward a hapten molecule; (ii) waiting a



sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and (iii) administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody.

Likewise, the methods for diagnosing and treating a malignancy may comprise administering a therapeutically effective amount of an anti-EGP-1 fusion protein or fragment thereof or a therapeutic conjugate comprising a EGP-1 MAb or fragment thereof, wherein the EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof is bound to at least one therapeutic agent in a pharmaceutically suitable excipient. In a related vein, naked anti-EGP-1 antibodies and fragments thereof, including naked anti-EGP-1 fusion proteins and fragments thereof, can also be used for treating a malignancy. Naked anti-EGP-1 antibodies may be used for *in vitro* diagnosis of a malignancy, for example with immunoassays or immunohistochemistry, but not for *in vivo* diagnosis, unless this involves a pretargeting technology, such as AES. Labeled EGP-1 antibodies, however, may be used for *in vivo* diagnosis and treatment of a malignancy. For example, described herein is a method of treating a cancer cell in a subject comprising (i) administering to a subject a therapeutically effective amount of a composition containing an anti-EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof (ii) formulating the EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof in a pharmaceutically suitable excipient. Similarly, combinations of naked MAbs and fragments thereof with conjugated MAbs or fragments thereof or fusion proteins or fragments thereof for diagnosis and treatment are also contemplated in the instant invention.

### BRIEF DESCRIPTION OF THE DRAWINGS

*Figure 1* shows a comparison of mRS7, cAb-V $\kappa$ #23 (cRS7), and cAb-V $\kappa$ #1 in competitive binding assays. Varying concentrations of competing Abs were used to compete with the binding of a constant amount of biotinylated mRS7 antibody. Results indicate that the V $\kappa$ #1 light chain does not bind the RS7 antigen.

*Figure 2* shows the DNA and amino acid sequences encoding (A) RS7 V $\kappa$  cloned by 5' RACE and (B) RS7 V $\text{H}$  cloned by RT-PCR. The putative CDR regions are

underlined and indicated. Nucleotide residues are numbered sequentially. Kabat's Ig molecule numbering is used for amino acid residues. In (B), the numbering for the residues with a letter (on top) is the number of preceding residues plus the letter, e.g., the number for T following N52 is 52A; the numbers for N, N and L following 182 are 82A, 82B and 82C, respectively.

*Figure 3* shows the amino acid sequence alignment of (A) human SA-1A'cl, murine RS7, and hRS7 V<sub>K</sub> chains and (B) human RF-TS3, murine RS7, and hRS7 V<sub>H</sub> chains. In (A), dots indicate the residues in RS7 are identical to the corresponding residues in SA-1A'cl. Dashes represent gaps introduced to aid the alignment. Boxed represent the CDR regions. Both N- and C-terminal residues (underlined) of hRS7 are fixed by the staging vector used. Therefore, the corresponding terminal residues of RS7 are not compared with that of the human sequence. Kabat's numbering scheme is used. In (B), dots indicate the residues in RS7 are identical to the corresponding residues in RF-TS3. Dashes represent gaps introduced to aid the alignment. Boxed represent the CDR regions. Both N- and C-terminal residues (underlined) of hRS7 are fixed by the staging vector used. Therefore, the corresponding terminal residues of RS7 are not compared with that of the human VH sequence.

*Figure 4* shows the DNA and amino acid sequences for (A) humanized RS7 V<sub>K</sub> and (B) humanized RS7 V<sub>H</sub>. The bold and underlined sections of the amino acid sequences indicate the CDRs as defined by the Kabat numbering scheme.

*Figure 5* shows the (A) light chain cDNA and amino acid sequences for humanized RS7 V<sub>K</sub> and heavy chain cDNA and amino acid sequences for humanized RS7 V<sub>H</sub>. The underlined sections of the amino acid sequences indicate the leader peptide sequence for secretion. "\*" indicates the stop codon.

*Figure 6* shows a comparison of mRS7, cRS7, and hRS7 in competitive binding assays. Varying concentrations of competing Abs were used to compete with the binding of a constant amount of Biotinylated RS7 to the Ag coated in 96-well ELISA plates. hRS7 showed comparable blocking activity as that of RS7 and cRS7.

*Figure 7* shows the light chain cDNA and amino acid sequences for humanized RS7 V<sub>K</sub>. The underlined sections of the amino acid sequences indicate the leader peptide sequence for secretion. "\*" indicates the stop codon. The lysine residues are also underlined.

*Figure 8* shows the heavy chain cDNA and amino acid sequences for humanized RS7 V<sub>K</sub>. The underlined sections of the amino acid sequences indicate the leader peptide sequence for secretion. "\*" indicates the stop codon. The lysine residues are also underlined.

*Figure 9* indicates the structure of the residualizing moieties IMP-R4, IMP-R5 and IMP-R8.

*Figure 10* is a bar graph of dosimetry due to radioiodinated hRS7 in the MDA-MB-468 tumor model.

*Figure 11* provides a series of graphs demonstrating the effects of radioimmunotherapy on tumor growth of breast cancer xenografts in nude mice.

*Figure 12* is a series of graphs evaluating toxicity after radioimmunotherapy treatment of breast cancer xenografts in nude mice.

*Figure 13* is a graph demonstrating relative mean tumor volumes (MTV).

## **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

Unless otherwise specified, "a" or "an" means "one or more."

An RS7 antibody (previously designated RS7-3G11) is a murine IgG<sub>1</sub> raised against a crude membrane preparation of a human primary squamous cell carcinoma from the lung. See Stein *et al.*, *Cancer Res.* 50: 1330 (1990), which is fully incorporated by reference. The RS7 antibody recognizes a tumor-associated antigen, which was defined by the murine MAb RS7-3G11 raised against human non-small-cell lung carcinoma. Stein *et al.* discloses that the RS7 antibody recognizes a 46-48 kDa glycoprotein, characterized as cluster 13. Stein *et al.*, *Int. J. Cancer Supp.* 8:98-102 (1994). See also, Basu *et al.*, *Int. J. Cancer* 52:472-479 (1995). The antigen has been designated as EGP-1

(epithelial glycoprotein-1) following the proposal of the 3<sup>rd</sup> International IASLC Workshop on Lung Tumor and Differentiation Antigens. See, for example DeLeij *et al.*, *Int. J. Cancer Supp.*, 8:60-63 (1994). Accordingly, as described herein, the RS7 and EGP-1 antigens are synonymous. The EGP-1 antigen is also referred to as TROP2 in the literature, but there may be multiple epitopes of both EGP-1 and TROP2.

Flow cytometry and immunohistochemical staining studies have shown that the RS7 MAb detects antigen on a variety of tumor types, with limited binding to normal human tissue. (Stein *et al.*, (1990), *supra*). The RS7 antibody is reactive with an EGP-1 glycoprotein, which can be rapidly internalized. EGP-1 is expressed primarily by carcinomas such as carcinomas of the lung, stomach, urinary bladder, breast, ovary, uterus, and prostate. Localization and therapy studies using radiolabeled murine RS7 MAb in animal models have demonstrated tumor targeting and therapeutic efficacy (Stein *et al.*, (1990), *supra*. Stein *et al.*, (1991), *supra*).

A more recent study has demonstrated strong RS7 staining in tumors from the lung, breast, bladder, ovary, uterus, stomach, and prostate. See Stein *et al.*, *Int. J. Cancer* 55: 938 (1993), which is fully incorporated by reference. Moreover, the lung cancer cases in this study comprised both squamous cell carcinomas and adenocarcinomas. *Id.* Both cell types stained strongly, indicating that the RS7 antibody does not distinguish between histologic classes of non-small-cell carcinoma of the lung.

As discussed *supra*, the RS7 MAb is rapidly internalized into target cells (Stein *et al.* (1993), *supra*). The internalization rate constant for RS7 MAb is intermediate between the internalization rate constants of two other rapidly internalizing MAbs which have been demonstrated to be useful for immunotoxin production. *Id.* It is well-documented that the internalization of immunotoxin conjugates is an absolute requirement for anti-tumor activity. (Pastan *et al.*, *Cell* 47:641 (1986)). Internalization of drug immunoconjugates also has been described as a major factor in anti-tumor efficacy. (Yang *et al.*, *Proc. Nat'l Acad. Sci. USA* 85: 1189 (1988)). Therefore, the RS7 antigen may be an important target for those types of immunotherapy that require internalization of the therapeutic agent.

Thus, studies with the RS7 MAb indicate that the antibody exhibits several important properties, which make it a candidate for clinical diagnostic and therapeutic applications. Since the RS7 antigen provides a useful target for diagnosis and therapy, it is desirable to obtain a MAb that recognizes an epitope of the RS7 antigen. Moreover, the availability of chimeric, humanized and human RS7 antibodies is essential for the development of a double-determinant enzyme-linked immunosorbent assay (ELISA), which is desirable for detecting the RS7 antigen in clinical samples, and essential for *in vivo* applications in humans.

To this end, the present invention describes chimeric, humanized and human antibodies and fragments thereof that bind the RS7 antigen and can be used for diagnostic and therapeutic methods. Humanized antibodies and antibody fragments are described in Provisional U.S. Application titled "Anti-CD20 Antibodies And Fusion Proteins Thereof And Methods Of Use", Attorney Docket No. 18733/1073, U.S. Provisional No. 60/356,132, U.S. Provisional Application No. 60/416,232 and Attorney Docket No. 18733/1155; hMN-14 antibodies, such as those disclosed in U.S. Application No. 5,874,540, which is a Class III anti-carcinoembryonic antigen antibody (anti-CEA antibody); Mu-9 antibodies, such as those described in U.S. Application No. 10/116,116; AFP antibodies, such as those described in U.S. Provisional Application No. 60/399,707; PAM4 antibodies, such as those described in Provisional U.S. Application titled "Monoclonal Antibody cPAM4", Attorney Docket No. 18733/1102; RS7 antibodies, such as those described in U.S. Provisional Application No. 60/360,229; and CD22 antibodies, such as those disclosed in U.S. Patent Nos. 5,789,554 and 6,187,287 and U.S. Application Nos. 09/741,843 and 09/988,013, all of which are incorporated herein by reference in their entirety. A chimeric antibody as disclosed herein is a recombinant protein that contains the variable domains including the complementarity determining regions (CDRs) of an antibody derived from one species, preferably a rodent antibody, while the constant domains of the antibody molecule is derived from those of a human antibody. For veterinary applications, the constant domains of the chimeric antibody may be derived from that of other species. A humanized antibody is a recombinant protein in which the CDRs from an antibody of one species, e.g., a rodent antibody, are transferred

from the heavy and variable chains of the rodent antibody into human heavy and light variable domains.

In a preferred embodiment, the RS7 antibody is humanized. Because non-human monoclonal antibodies can be recognized by the human host as a foreign protein, and repeated injections can lead to harmful hypersensitivity reactions, humanization of a murine RS7 sequences can reduce the adverse immune response that patients may experience. For murine-based monoclonal antibodies, this is often referred to as a Human Anti-Mouse Antibody (HAMA) response. Another embodiment of the present invention is an anti-EGF-1 antibody or fragment thereof that is a subhuman primate anti-EGF-1 antibody, murine monoclonal anti-EGF-1 antibody (restricted to veterinary applications), chimeric anti-EGF-1 antibody, human anti-EGF-1 antibody, and humanized anti-EGF-1 antibody. Preferably some human residues in the framework regions of the humanized RS7 antibody or fragments thereof are replaced by their murine counterparts. It is also preferred that a combination of framework sequences from 2 different human antibodies are used for  $V_H$ . The constant domains of the antibody molecule are derived from those of a human antibody.

Another preferred embodiment of the present invention is a human RS7 antibody. A human antibody is an antibody obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green *et al.*, *Nature Genet.* 7:13 (1994), Lonberg *et al.*, *Nature* 368:856 (1994), and Taylor *et al.*, *Int. Immun.* 6:579 (1994). A fully human antibody also can be constructed by genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art. See for example, McCafferty *et al.*, *Nature* 348:552-553 (1990) for the production of human antibodies and fragments thereof *in vitro*, from immunoglobulin variable domain gene repertoires

from unimmunized donors. In this technique, antibody variable domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. In this way, the phage mimics some of the properties of the B cell. Phage display can be performed in a variety of formats, for their review, see e.g. Johnson and Chiswell, *Current Opinion in Structural Biology* 3:5564-571 (1993).

The antibody and fragments thereof of the present invention is preferably raised against a crude membrane preparation from a human primary squamous cell carcinoma of the lung. Also preferred, the RS7 antibody and fragments thereof is raised against a membrane preparation of viable cells from a human ovarian carcinoma cell line. Still preferred, the RS7 antigen is provided by viable Colo 316 cells. In a related vein, the RS7 antibody can be obtained using a substantially pure preparation of the RS7 antigen. A substantially pure protein is a protein that is essentially free from contaminating cellular components, which are associated with the protein in nature. As described herein, the term "RS7 antibody" also includes chimeric, human and humanized RS7 antibodies.

#### **Preparation of chimeric, humanized and human RS7 antibodies**

Monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example, Kohler and Milstein, *Nature* 256: 495 (1975), and Coligan *et al.* (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991) (hereinafter "Coligan"). Briefly, RS7 antigen MAbs, such as RS7, can be obtained by injecting mice with a composition comprising the RS7 antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to RS7 antigen, culturing the clones that produce antibodies to RS7 antigen, and isolating RS7 antibodies from the hybridoma cultures.

After the initial raising of antibodies to the immunogen, the antibodies can be sequenced and subsequently prepared by recombinant techniques. Humanization and chimerization of murine antibodies and antibody fragments are well known to those skilled in the art. For example, humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then, substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions.

A human antibody of the present invention, i.e., human EGP-1 MAbs or other human antibodies, such as anti-EGP-2, MUC1-4, CEA, CC49, CSAp, PSMA, PSA, EGFR, A33 and HER2/neu MAbs for combination therapy with humanized, chimeric or human RS7 antibodies, can be obtained from a transgenic non-human animal. See, e.g., Mendez *et al.*, *Nature Genetics*, 15: 146-156 (1997); U.S. Patent No. 5,633,425, which are incorporated in their entirety by reference. A human antibody of the present invention that can be used for combination therapy may also be reactive with an antigen selected from the group consisting of Le(y), Tn, Tag-72, AFP, HCG, HCG-beta, ferritin, PAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, or a combination thereof. For example, a human antibody can be recovered from a transgenic mouse possessing human immunoglobulin loci. The mouse humoral immune system is humanized by inactivating the endogenous immunoglobulin genes and introducing human immunoglobulin loci. The human immunoglobulin loci are exceedingly complex and comprise a large number of discrete segments which together occupy almost 0.2% of the human genome. To ensure that transgenic mice are capable of producing adequate repertoires of antibodies, large portions of human heavy- and light-chain loci must be introduced into the mouse genome. This is accomplished in a stepwise process beginning with the formation of yeast artificial chromosomes (YACs) containing either human heavy- or light-chain immunoglobulin loci in germline configuration. Since each insert is approximately 1 Mb in size, YAC construction requires homologous recombination of overlapping fragments of the immunoglobulin loci. The two YACs,



one containing the heavy-chain loci and one containing the light-chain loci, are introduced separately into mice via fusion of YAC-containing yeast spheroblasts with mouse embryonic stem cells. Embryonic stem cell clones are then microinjected into mouse blastocysts. Resulting chimeric males are screened for their ability to transmit the YAC through their germline and are bred with mice deficient in murine antibody production. Breeding the two transgenic strains, one containing the human heavy-chain loci and the other containing the human light-chain loci, creates progeny which produce human antibodies in response to immunization.

General techniques for cloning murine immunoglobulin variable domains are described, for example, by the publication of Orlandi *et al.*, *Proc. Nat'l Acad. Sci. USA* 86: 3833 (1989), which is incorporated by reference in its entirety. Techniques for producing humanized MAbs are described, for example, by Carter *et al.*, *Proc. Nat'l Acad. Sci. USA* 89: 4285 (1992), Singer *et al.*, *J. Immun.* 150: 2844 (1992), Mountain *et al.* *Biotechnol. Genet. Eng. Rev.* 10: 1 (1992), and Coligan at pages 10.19.1-10.19.11, each of which is hereby incorporated by reference.

In general, the V $\kappa$  (variable light chain) and V $\mu$  (variable heavy chain) sequences for RS7 antibodies can be obtained by a variety of molecular cloning procedures, such as RT-PCR, 5'-RACE, and cDNA library screening. Specifically, the V $\mu$  and V $\kappa$  genes of the MAb RS7 were cloned by PCR amplification from the hybridoma cells by RT-PCR and 5' RACE, respectively, and their sequences determined by DNA sequencing. To confirm their authenticity, the cloned V $\mu$  and V $\kappa$  genes can be expressed in cell culture as a chimeric Ab as described by Orlandi *et al.*, (*Proc. Natl. Acad. Sci.*, USA, 86: 3833 (1989)) which is incorporated by reference. Based on the V gene sequences, a humanized RS7 antibody can then be designed and constructed as described by Leung *et al.* (*Mol. Immunol.*, 32: 1413 (1995)), which is incorporated by reference. cDNA can be prepared from any known hybridoma line or transfected cell line producing a murine or chimeric RS7 antibody by general molecular cloning techniques (Sambrook *et al.*, *Molecular Cloning, A laboratory manual*, 2<sup>nd</sup> Ed (1989)). In a preferred embodiment, the RS7 hybridoma line is used. The V $\kappa$  sequence for the mAb may be amplified using the primers VK1BACK and VK1FOR (Orlandi *et al.*, 1989) or the extended primer set described by Leung *et al.* (*BioTechniques*,

15: 286 (1993)), which is incorporated by reference, while  $V_H$  sequences can be amplified using the primer pair VH1BACK/VH1FOR (Orlandi *et al.*, 1989 above), or the primers annealing to the constant region of murine IgG described by Leung et al. (Hybridoma, 13:469 (1994)), which is incorporated by reference. The PCR reaction mixtures containing 10  $\mu$ l of the first strand cDNA product, 10  $\mu$ l of 10X PCR buffer [500 mM KCl, 100 mM Tris-HCl (pH 8.3), 15 mM  $MgCl_2$ , and 0.01% (w/v) gelatin] (Perkin Elmer Cetus, Norwalk, CT), 250  $\mu$ M of each dNTP, 200 nM of the primers, and 5 units of Taq DNA polymerase (Perkin Elmer Cetus) can be subjected to 30 cycles of PCR. Each PCR cycle preferably consists of denaturation at 94°C for 1 min, annealing at 50°C for 1.5 min, and polymerization at 72°C for 1.5 min. Amplified  $V_k$  and  $V_H$  fragments can be purified on 2% agarose (BioRad, Richmond, CA). Similarly, the humanized V genes can be constructed by a combination of long oligonucleotide template syntheses and PCR amplification as described by Leung et al. (*Mol. Immunol.*, 32: 1413 (1995)).

PCR products for  $V_k$  can be subcloned into a staging vector, such as a pBR327-based staging vector, VKpBR, that contains an Ig promoter, a signal peptide sequence and convenient restriction sites to facilitate in-frame ligation of the  $V_k$  PCR products. PCR products for  $V_H$  can be subcloned into a similar staging vector, such as the pBluescript-based VHpBS. Individual clones containing the respective PCR products may be sequenced by, for example, the method of Sanger *et al.* (*Proc. Natl. Acad. Sci.*, USA, 74: 5463 (1977)), which is incorporated by reference.

The DNA sequences described herein are to be taken as including all alleles, mutants and variants thereof, whether occurring naturally or induced.

The expression cassettes containing the  $V_k$  and  $V_H$ , together with the promoter and signal peptide sequences can be excised from VKpBR and VHpBS, respectively, by double restriction digestion as HindIII-BamHI fragments. The  $V_k$  and  $V_H$  expression cassettes can then be ligated into appropriate expression vectors, such as pKh and pGlg, respectively (Leung et al., Hybridoma, 13:469 (1994)). The expression vectors can be co-transfected into an appropriate cell, e.g., myeloma Sp2/0-Ag14 (ATCC, VA), colonies selected for hygromycin resistance, and supernatant fluids monitored for production of a chimeric or

humanized RS7 MAb by, for example, an ELISA assay, as described below. Alternately, the V $\kappa$  and V $\text{H}$  expression cassettes can be assembled in the modified staging vectors, VKpBR2 and VHpBS2, excised as XbaI/BamHI and XhoI/BamHI fragments, respectively, and subcloned into a single expression vector, such as pdHL2, as described by Gilles *et al.* (*J. Immunol. Methods* 125:191 (1989) and also shown in Losman *et al.*, *Cancer*, 80:2660 (1997)) for the expression in Sp2/0-Ag14 cells. Another vector that is useful in the present invention is the GS vector, as described in Barnes *et al.*, *Cytotechnology* 32:109-123 (2000), which is preferably expressed in the NS0 cell line and CHO cells. Other appropriate mammalian expression systems are described in Werner *et al.*, *Arzneim.-Forsch./Drug Res.* 48(II), Nr. 8, 870-880 (1998).

Co-transfection and assay for antibody secreting clones by ELISA, can be carried out as follows. About 10  $\mu\text{g}$  of VKpKh (light chain expression vector) and 20  $\mu\text{g}$  of VHpG1g (heavy chain expression vector) can be used for the transfection of  $5 \times 10^6$  SP2/0 myeloma cells by electroporation (BioRad, Richmond, CA) according to Co *et al.*, *J. Immunol.*, 148: 1149 (1992) which is incorporated by reference. Following transfection, cells may be grown in 96-well microtiter plates in complete HSFM medium (Life Technologies, Inc., Grand Island, NY) at 37°C, 5%CO<sub>2</sub>. The selection process can be initiated after two days by the addition of hygromycin selection medium (Calbiochem, San Diego, CA) at a final concentration of 500 units/ml of hygromycin. Colonies typically emerge 2-3 weeks post-electroporation. The cultures can then be expanded for further analysis.

Suitable host cells include microbial or mammalian host cells. A preferred host is the human cell line, PER.C6, which was developed for production of MAbs, and other fusion proteins. Accordingly, a preferred embodiment of the present invention is a host cell comprising a DNA sequence encoding and anti-EGP-1 MAb, conjugate, fusion protein or fragments thereof. PER.C6 cells (WO 97/00326) were generated by transfection of primary human embryonic retina cells, using a plasmid that contained the Adserotype 5 (Ad5) E1A- and E1B-coding sequences (Ad5 nucleotides 459-3510) under the control of the human phosphoglycerate kinase (PGK) promoter. E1A and E1B are adenovirus early gene activation protein 1A and 1B, respectively. The methods and

compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, e.g. by glycosylation. Several features make PER.C6 particularly useful as a host for recombinant protein production, such as PER.C6 is a fully characterized human cell line and it was developed in compliance with good laboratory practices. Moreover, PER.C6 can be grown as a suspension culture in defined serum-free medium devoid of any human- or animal-derived proteins and its growth is compatible with roller bottles, shaker flasks, spinner flasks and bioreactors with doubling times of about 35 hrs. Finally, the presence of E1A causes an up regulation of expression of genes that are under the control of the CMV enhancer /promoter and the presence of E13 prevents p53-dependent apoptosis possibly enhanced through over expression of the recombinant transgene. In one embodiment, the cell is capable of producing 2 to 200-fold more recombinant protein and/or proteinaceous substance than conventional mammalian cell lines.

Transfectoma clones that are positive for the secretion of chimeric or humanized heavy chain can be identified by ELISA assay. Briefly, supernatant samples (~100 µl) from transfectoma cultures are added in triplicate to ELISA microtiter plates precoated with goat anti-human (GAH)-IgG, F(ab')<sub>2</sub> fragment-specific antibody (Jackson ImmunoResearch, West Grove, PA). Plates are incubated for 1 h at room temperature. Unbound proteins are removed by washing three times with wash buffer (PBS containing 0.05% polysorbate 20). Horseradish peroxidase (HRP) conjugated GAH-IgG, Fc fragment-specific antibodies (Jackson ImmunoResearch) are added to the wells, (100 µl of antibody stock diluted  $\times 10^4$ , supplemented with the unconjugated antibody to a final concentration of 1.0 µg/ml). Following an incubation of 1 h, the plates are washed, typically three times. A reaction solution, [100 µl, containing 167 µg of orthophenylene-diamine (OPD) (Sigma, St. Louis, MO), 0.025% hydrogen peroxide in PBS], is added to the wells. Color is allowed to develop in the dark for 30 minutes. The reaction is stopped by the addition of 50 µl of 4 N HCl solution into each well before measuring absorbance at 490 nm in an automated ELISA reader (Bio-Tek instruments, Winooski, VT). Bound chimeric antibodies are then determined relative to an irrelevant chimeric antibody standard (obtainable from Scotgen, Ltd., Edinburg, Scotland).

Antibodies can be isolated from cell culture media as follows. Transfectoma cultures are adapted to serum-free medium. For production of chimeric antibody, cells are grown as a 500 ml culture in roller bottles using HSFM. Cultures are centrifuged and the supernatant filtered through a 0.2  $\mu$  membrane. The filtered medium is passed through a protein A column (1 x 3 cm) at a flow rate of 1 ml/min. The resin is then washed with about 10 column volumes of PBS and protein A-bound antibody is eluted from the column with 0.1 M glycine buffer (pH 3.5) containing 10 mM EDTA. Fractions of 1.0 ml are collected in tubes containing 10  $\mu$ l of 3 M Tris (pH 8.6), and protein concentrations determined from the absorbance at 280/260 nm. Peak fractions are pooled, dialyzed against PBS, and the antibody concentrated, for example, with the Centricon 30 (Amicon, Beverly, MA). The antibody concentration is determined by ELISA, as before, and its concentration adjusted to about 1 mg/ml using PBS. Sodium azide, 0.01% (w/v), is conveniently added to the sample as preservative.

The nucleotide sequences of the primers used to prepare the RS7 antibodies are listed in Example 2, below. In a preferred embodiment, a humanized RS7 antibody or antibody fragment comprises the complementarity-determining regions (CDRs) of a murine RS7 MAb and the framework (FR) regions of the light and heavy chain variable regions of a human antibody and the light and heavy chain constant regions of a human antibody, wherein the CDRs of the light chain variable region of the humanized RS7 comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT; and the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV. Also preferred, the FRs of the light and heavy chain variable regions of the humanized antibody comprise at least one amino acid substituted from said corresponding FRs of the murine RS7 MAb.

RS7 MAbs can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange

chromatography. See, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3. Also, see Baines *et al.*, "Purification of Immunoglobulin G (IgG)," in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992).

RS7 MAbs can be characterized by a variety of techniques that are well-known to those of skill in the art. For example, the ability of an RS7 MAb to bind to the RS7 antigen can be verified using an indirect immunofluorescence assay, flow cytometry analysis, or Western analysis.

### **Production of RS7 Antibody Fragments**

The present invention contemplates the use of fragments of RS7 and hRS7 antibodies. Antibody fragments which recognize specific epitopes can be generated by known techniques. The antibody fragments are antigen binding portions of an antibody, such as F(ab')<sub>2</sub>, Fab', Fab, Fv, sFv and the like. Other antibody fragments include, but are not limited to: the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab' fragments, which can be generated by reducing disulfide bridges of the F(ab')<sub>2</sub> fragments. These methods are described, for example, by Goldenberg, U.S. patent Nos. 4,036,945 and 4,331,647 and references contained therein, which patents are incorporated herein in their entireties by reference. Also, see Nisonoff *et al.*, *Arch Biochem. Biophys.* 89: 230 (1960); Porter, *Biochem. J.* 73: 119 (1959), Edelman *et al.*, in METHODS IN ENZYMOLOGY VOL. 1, page 422 (Academic Press 1967), and Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4. Alternatively, Fab' expression libraries can be constructed (Huse *et al.*, 1989, *Science*, 246:1274-1281) to allow rapid and easy identification of monoclonal Fab' fragments with the desired specificity. The present invention encompasses antibodies and antibody fragments.

A single chain Fv molecule (scFv) comprises a VL domain and a VH domain. The VL and VH domains associate to form a target binding site. These two domains are further covalently linked by a peptide linker (L). A scFv molecule is denoted as either VL-L-VH if the VL domain is the N-terminal part of the scFv molecule, or as VH-L-VL if the VH domain is the N-terminal part of the scFv molecule. Methods for making scFv molecules and designing suitable peptide linkers are described in US Patent No.

4,704,692, US Patent No. 4,946,778, R. Raag and M. Whitlow, "*Single Chain Fvs.*" FASEB Vol 9:73-80 (1995) and R.E. Bird and B.W. Walker, "*Single Chain Antibody Variable Regions*," TIBTECH, Vol 9: 132-137 (1991). These references are incorporated herein by reference.

An antibody fragment can be prepared by proteolytic hydrolysis of the full length antibody or by expression in *E. coli* or another host of the DNA coding for the fragment. An antibody fragment can be obtained by pepsin or papain digestion of full length antibodies by conventional methods. For example, an antibody fragment can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')<sub>2</sub>. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using papain produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Patent Nos. 4,036,945 and 4,331,647 and references contained therein, which patents are incorporated herein in their entireties by reference. Also, see Nisonoff *et al.*, *Arch Biochem. Biophys.* 89: 230 (1960); Porter, *Biochem. J.* 73: 119 (1959), Edelman *et al.*, in METHODS IN ENZYMOLOGY VOL. 1, page 422 (Academic Press 1967), and Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). A CDR is a segment of the variable region of an antibody that is complementary in structure to the epitope to which the antibody binds and is more variable than the rest of the variable region. Accordingly, a CDR is sometimes referred to as hypervariable region. A variable region comprises three CDRs. CDR peptides can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick *et al.*, *Methods: A Companion to Methods in Enzymology* 2: 106 (1991); Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL

APPLICATION, Ritter *et al.* (eds.), pages 166-179 (Cambridge University Press 1995); and Ward *et al.*, "Genetic Manipulation and Expression of Antibodies," in MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, Birch *et al.*, (eds.), pages 137-185 (Wiley-Liss, Inc. 1995).

Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

#### **Production of chimeric, humanized and human RS7 antibody fusion proteins**

Antibody fusion proteins and fragments thereof can be prepared by a variety of conventional procedures, ranging from glutaraldehyde linkage to more specific linkages between functional groups. The antibodies and/or antibody fragments are preferably covalently bound to one another, directly or through a linker moiety, through one or more functional groups on the antibody or fragment, e.g., amine, carboxyl, phenyl, thiol, or hydroxyl groups. Various conventional linkers in addition to glutaraldehyde can be used, e.g., diisocyanates, diisothiocyanates, bis(hydroxysuccinimide) esters, carbodiimides, maleimidehydroxysuccinimide esters, and the like.

A simple method to produce chimeric, humanized and human RS7 antibody fusion proteins is to mix the antibodies or fragments in the presence of glutaraldehyde to form an antibody fusion protein. The initial Schiff base linkages can be stabilized, e.g., by borohydride reduction to secondary amines. A diisothiocyanate or carbodiimide can be used in place of glutaraldehyde as a non-site-specific linker. Antibody fusion proteins are expected to have a greater binding specificity than MAbs, since the fusion proteins comprise moieties that bind to at least two epitopes of the RS7 antigen. Thus, antibody fusion proteins are the preferred form of RS7 antigen binding protein for therapy.

In the present context, an antibody fusion protein comprises at least two chimeric, humanized or human RS7 MAbs, or fragments thereof, wherein at least two of the MAbs or fragments bind to different epitopes of the RS7 antigen or against an RS7 epitope and that of a totally different antigen. For example, a bispecific RS7 antibody fusion protein



may comprise a CEA antibody or fragment thereof and the RS7 MAb or fragment thereof. Such a bispecific RS7 antibody fusion protein can be prepared, for example, by obtaining an  $F(ab')_2$  fragment from CEA as described above. The interchain disulfide bridges of the antibody  $F(ab')_2$  fragment are gently reduced with cysteine, taking care to avoid light-heavy chain linkage, to form Fab'-SH fragments. The SH group(s) is (are) activated with an excess of bis-maleimide linker (1,1'-(methylenedi-4, 1-phenylene)bis-maleimide). The RS7 MAb is converted to Fab'-SH and then reacted with the activated CEA Fab'-SH fragment to obtain a bispecific RS7 antibody fusion protein.

A polyspecific RS7 antibody fusion protein can be obtained by adding RS7 antigen binding moieties to a bispecific chimeric, humanized or human RS7 antibody fusion protein. For example, a bispecific antibody fusion protein can be reacted with 2-iminothiolane to introduce one or more sulfhydryl groups for use in coupling the bispecific fusion protein to a third RS7 antigen MAb or fragment, using the bis-maleimide activation procedure described above. These techniques for producing antibody composites are well known to those of skill in the art. See, for example, U.S. patent No. 4,925,648, which is incorporated by reference in its entirety.

Bispecific antibodies can be made by a variety of conventional methods, e.g., disulfide cleavage and reformation of mixtures of whole IgG or, preferably  $F(ab')_2$  fragments, fusions of more than one hybridoma to form polyomas that produce antibodies having more than one specificity, and by genetic engineering. Bispecific antibody fusion proteins have been prepared by oxidative cleavage of Fab' fragments resulting from reductive cleavage of different antibodies. This is advantageously carried out by mixing two different  $F(ab')_2$  fragments produced by pepsin digestion of two different antibodies, reductive cleavage to form a mixture of Fab' fragments, followed by oxidative reformation of the disulfide linkages to produce a mixture of  $F(ab')_2$  fragments including bispecific antibody fusion proteins containing a Fab' portion specific to each of the original epitopes. General techniques for the preparation of antibody fusion proteins may be found, for example, in Nisonoff *et al.*, *Arch Biochem. Biophys.* 93: 470 (1961), Hämmerling *et al.*, *J. Exp. Med.* 128: 1461 (1968), and U.S. patent No. 4,331,647. Contemplated in the present invention is an antibody fusion protein or fragment thereof

comprising at least one first anti-EGP-1 MAb or fragment thereof and at least one second MAb or fragment thereof, other than the anti-EGP-1 MAbs or fragments thereof of the present invention.

More selective linkage can be achieved by using a heterobifunctional linker such as maleimidehydroxysuccinimide ester. Reaction of the ester with an antibody or fragment will derivatize amine groups on the antibody or fragment, and the derivative can then be reacted with, e.g., and antibody Fab fragment having free sulfhydryl groups (or, a larger fragment or intact antibody with sulfhydryl groups appended thereto by, e.g., Traut's Reagent). Such a linker is less likely to crosslink groups in the same antibody and improves the selectivity of the linkage.

It is advantageous to link the antibodies or fragments at sites remote from the antigen binding sites. This can be accomplished by, e.g., linkage to cleaved interchain sulfhydryl groups, as noted above. Another method involves reacting an antibody having an oxidized carbohydrate portion with another antibody which has at least one free amine function. This results in an initial Schiff base (imine) linkage, which is preferably stabilized by reduction to a secondary amine, e.g., by borohydride reduction, to form the final composite. Such site-specific linkages are disclosed, for small molecules, in U.S. patent No. 4,671,958, and for larger addends in U.S. patent No. 4,699,784 - incorporated by reference.

ScFvs with linkers greater than 12 amino acid residues in length (for example, 15- or 18-residue linkers) allow interacting between the  $V_H$  and  $V_L$  domains on the same chain and generally form a mixture of monomers, dimers (termed diabodies) and small amounts of higher mass multimers, (Kortt *et al.*, Eur. J. Biochem. (1994) 221: 151-157). ScFvs with linkers of 5 or less amino acid residues, however, prohibit intramolecular pairing of the  $V_H$  and  $V_L$  domains on the same chain, forcing pairing with  $V_H$  and  $V_L$  domains on a different chain. Linkers between 3- and 12-residues form predominantly dimers (Atwell *et al.*, Protein Engineering (1999) 12: 597-604). With linkers between 0 and 2 residues, trimeric (termed triabodies), tetrameric (termed tetrabodies) or higher oligomeric structures of scFvs are formed; however, the exact patterns of oligomerization appear to depend on the composition as well as the orientation of the V-domains, in

addition to the linker length. For example, scFvs of the anti-neuraminidase antibody NC10 formed predominantly trimers ( $V_H$  to  $V_L$  orientation) or tetramers ( $V_L$  to  $V_H$  orientation) with 0-residue linkers (Dolezal *et al.*, Protein Engineering (2000) 13: 565-574). For scFvs constructed from NC10 with 1- and 2-residue linkers, the  $V_H$  to  $V_L$  orientation formed predominantly diabodies (Atwell *et al.*, Protein Engineering (1999) 12: 597-604); in contrast, the  $V_L$  to  $V_H$  orientation formed a mixture of tetramers, trimers, dimers, and higher mass multimers (Dolezal *et al.*, Protein Engineering (2000) 13: 565-574). For scFvs constructed from the anti-CD19 antibody HD37 in the  $V_H$  to  $V_L$  orientation, the 0-residue linker formed exclusively trimers and the 1-residue linker formed exclusively tetramers (Le Gall *et al.*, FEBS Letters (1999) 453: 164-168).

The RS7 antibodies and fragments thereof of the present invention can also be used to produce antigen-specific diabodies, triabodies and tetrabodies, which are multivalent but monospecific. The non-covalent association of two or more scFv molecules can form functional diabodies, triabodies and tetrabodies. Monospecific diabodies are homodimers of the same scFv, where each scFv comprises the  $V_H$  domain from the selected antibody connected by a short linker to the  $V_L$  domain of the same antibody. A diabody is a bivalent dimer formed by the non-covalent association of two scFvs, yielding two Fv binding sites. A triabody results from the formation of a trivalent trimer of three scFvs, yielding three binding sites, and a tetrabody is a tetravalent tetramer of four scFvs, resulting in four binding sites. Several monospecific diabodies have been made using an expression vector that contains a recombinant gene construct comprising  $V_{H1}$ -linker- $V_{L1}$ . See Holliger *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Atwell *et al.*, *Molecular Immunology* 33: 1301-1302 (1996); Holliger *et al.*, *Nature Biotechnology* 15: 632-631(1997); Helfrich *et al.*, *Int. J. Cancer* 76: 232-239 (1998); Kipriyanov *et al.*, *Int. J. Cancer* 77: 763-772 (1998); Holiger *et al.*, *Cancer Research* 59: 2909-2916(1999)). Methods of constructing scFvs are disclosed in US-4,946,778 (1990) and US-5,132,405 (1992). Methods of producing multivalent, monospecific binding proteins based on scFv are disclosed in US-5,837,242 (1998), US-5,844,094 (1998) and WO-98/44001 (1998). A preferred embodiment of the instant invention is a multivalent, multispecific antibody or fragment thereof comprising one or more antigen binding sites

having affinity toward an EGP-1 target antigen and one or more hapten binding sites having affinity towards hapten molecules.

### **Determining antibody binding affinity**

Comparative binding affinities of the mRS7, cRS7 and hRS7 antibodies thus isolated may be determined by direct radioimmunoassay. RS7 can be labeled with  $^{131}\text{I}$  or  $^{125}\text{I}$  using the chloramines-T method (*see, for example, Greenwood et al., Biochem. J.*, 89: 123 (1963) which is incorporated by reference). The specific activity of the iodinated antibody is typically adjusted to about 10  $\mu\text{Ci}/\mu\text{g}$ . Unlabeled and labeled antibodies are diluted to the appropriate concentrations using reaction medium (HSFM supplemented with 1% horse serum and 100  $\mu\text{g}/\text{ml}$  gentamicin). The appropriate concentrations of both labeled and unlabeled antibodies are added together to the reaction tubes in a total volume of 100  $\mu\text{l}$ . A culture of ME180 cells (a human cervical carcinoma cell line) is sampled and the cell concentration determined. The culture is centrifuged and the collected cells washed once in reaction medium followed by resuspension in reaction medium to a final concentration of about  $10^7$  cells/ml. All procedures are carried out in the cold at 4° C. The cell suspension, 100  $\mu\text{l}$ , is added to the reaction tubes. The reaction is carried out at 4° C. for 2 h with periodic gentle shaking of the reaction tubes to resuspend the cells. Following the reaction period, 5 ml of wash buffer (PBS containing 1% BSA) is added to each tube. The suspension is centrifuged and the cell pellet washed a second time with another 5 ml of wash buffer. Following centrifugation, the amount of remaining radioactivity remaining in the cell pellet is determined in a gamma counter (Minaxi, Packard Instruments, Sterling, Va.).

### **Expression vectors**

An expression vector is a DNA molecule comprising a gene that is expressed in a host cell. Typically, gene expression is placed under the control of certain regulatory elements, including constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. Such a gene is said to be “operably linked to” the regulatory elements. A promoter is a DNA sequence that directs the transcription of a structural gene. A structural gene is a DNA sequence that is transcribed into messenger RNA

(mRNA) which is then translated into a sequence of amino acids characteristic of a specific polypeptide. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. An enhancer is a DNA regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.

An isolated DNA molecule is a fragment of DNA that is not integrated in the genomic DNA of an organism. For example, a cloned RS7 antigen gene is a DNA fragment that has been separated from the genomic DNA of a mammalian cell. Another example of an isolated DNA molecule is a chemically-synthesized DNA molecule that is not integrated in the genomic DNA of an organism. Complementary DNA (cDNA) is a single-stranded DNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of reverse transcription. Those skilled in the art also use the term "cDNA" to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand.

A cloning vector is a DNA molecule, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign DNA sequences can be inserted in a determinable fashion without loss of an essential biological function of the vector, as well as a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance. A recombinant host may be any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector. This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell. The term expression refers to the biosynthesis of a gene product. For example, in the case of a structural gene,

expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.

**Humanized, human and chimeric RS7 antibodies use for treatment and diagnosis**

Contemplated in the present invention is a method of diagnosing or treating a malignancy in a subject comprising administering to the subject a therapeutically effective amount of a therapeutic conjugate comprising an EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof, wherein the EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof is bound to at least one therapeutic agent and then formulated in a pharmaceutically suitable excipient. It is also contemplated that an unconjugated (naked) EGP-1 MAb or fusion construct with other antigen-binding moieties also can be used as a therapeutic for cancer cells expressing EGP-1. These unconjugated antibodies may be given advantageously in combination with other therapeutic modalities, such as chemotherapy, radiotherapy, and/or immunotherapy, either together or in various sequences and schedules. Also preferred is a method for diagnosing or treating cancer, comprising: administering a multivalent, multispecific antibody or fragment thereof comprising one or more antigen binding sites toward a EGP-1 antigen and one or more hapten binding sites to a subject in need thereof, waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and then administering to the subject a carrier molecule comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to the binding site of the multivalent, multispecific antibody or fragment thereof. In a preferred embodiment, the cancer is a lung, breast, head and neck, ovarian, prostate, bladder or colon cancer.

Hybridoma technology for the production of monoclonal antibodies (MAbs) has provided a method for the production of molecular probes capable of locating or killing cancer cells. Tumor imaging techniques using radiolabeled MAbs have been used to delineate cancerous invasion in a number of malignancies. In experimental animals and in humans, antibodies have been used for the radioimmunodetection of carcinoembryonic antigen in diverse tumors that express carcinoembryonic antigen, and also tumors such as

melanoma, colon carcinoma, and breast carcinoma with other targeting antibodies.

Goldenberg *et al.*, *Cancer Res.* 40: 2984 (1980); Hwang *et al.*, *Cancer Res.* 45: 4150 (1985); Zalcborg *et al.*, *J. Nat'l Cancer Inst.* 71: 801 (1983); Colcher *et al.*, *Cancer Res.* 43: 736 (1983); (Larson *et al.*, *J. Nucl. Med.* 24: 123 (1983); DeLand *et al.*, *Cancer Res.* 40: 3046 (1980); Epenetos *et al.*, *Lancet* 2: 999 (1982).

The use of MAbs for *in vitro* diagnosis is well-known. See, for example, Carlsson *et al.*, *Bio/Technology* 7 (6): 567 (1989). For example, MAbs can be used to detect the presence of a tumor-associated antigen in tissue from biopsy samples. MAbs also can be used to measure the amount of tumor-associated antigen in clinical fluid samples using techniques such as radioimmunoassay, enzyme-linked immunosorbent assay, and fluorescence immunoassay.

Conjugates of tumor-targeted MAbs and toxins can be used to selectively kill cancer cells *in vivo* (Spalding, *Bio/Technology* 9(8): 701 (1991); Goldenberg, *Scientific American Science & Medicine* 1(1): 64 (1994)). For example, therapeutic studies in experimental animal models have demonstrated the anti-tumor activity of antibodies carrying cytotoxic radionuclides. (Goldenberg *et al.*, *Cancer Res.* 41: 4354 (1981), Cheung *et al.*, *J. Nat'l Cancer Inst.* 77: 739 (1986), and Senekowitsch *et al.*, *J. Nucl. Med.* 30: 531 (1989)). Also, see Stein *et al.*, *Antibody Immunoconj. Radiopharm.* 4: 703 (1991), which is fully incorporated by reference. Moreover, Phase-I therapeutic trials with some of these MAbs have been initiated for treatment of lymphoma, melanoma, and other malignancies. See, for example, DeNardo *et al.*, *Int. J. Cancer Suppl.* 3: 96 (1988), and Goldenberg *et al.*, *J. Clin. Oncol.* 9: 548 (1991).

Humanized, chimeric and fully human antibodies and fragments thereof are suitable for use in therapeutic methods and diagnostic methods. Accordingly, contemplated in the present invention is a method of delivering a diagnostic or therapeutic agent, or a combination thereof, to a target comprising (i) providing a composition that comprises an anti-EGP-1 antibody and (ii) administering to a subject in need thereof the diagnostic or therapeutic antibody conjugate. Preferably, the chimeric, humanized and fully human RS7 antibodies and fragments thereof of the present invention are used in methods for treating malignancies.

Also described herein is a cancer cell targeting diagnostic or therapeutic conjugate comprising an antibody component comprising an anti-EGP-1 mAb or fragment thereof or an antibody fusion protein or fragment thereof that binds to the cancer cell, wherein the antibody component is bound to at least one diagnostic or at least one therapeutic agent. Preferably, the diagnostic conjugate comprises at least a photoactive diagnostic agent or an MRI contrast agent. Still preferred, the diagnostic agent is a radioactive label with an energy between 60 and 4,000 keV.

The compositions for treatment contain at least one naked or conjugated humanized, chimeric or human RS7 antibody alone, or in combination with other naked or conjugated humanized, chimeric, human or other antibodies of the present invention, or other naked or conjugated humanized, chimeric or human antibodies not disclosed herein. The present invention also contemplates administration of a conjugated or naked antibody with a therapeutic agent such as an immunomodulator, or diagnostic agent that is not conjugated to the anti-EGP-1 antibody. Naked or conjugated antibodies to the same or different epitope or antigen may be also combined with one or more of the antibodies of the present invention.

Accordingly, the present invention contemplates the administration anti-EGP-1 antibodies and fragments thereof alone, as a naked antibody or antibody fragment, or administered as a multimodal therapy. Preferably, the antibody is a humanized, chimeric or fully human RS7 antibody or fragment thereof. Multimodal therapies of the present invention further include immunotherapy with a naked anti-EGP-1 antibody supplemented with administration of other antibodies in the form of naked antibodies, fusion proteins, or as immunoconjugates. For example, a humanized, chimeric or fully human RS7 antibody may be combined with another naked humanized, chimeric RS7 or other antibody, or a humanized, chimeric RS7 or other antibody conjugated to an isotope, one or more chemotherapeutic agents, cytokines, toxins or a combination thereof. For example, the present invention contemplates treatment of a naked or conjugated EGP-1 or RS7 antibody or fragments thereof before, in combination with, or after other solid tumor/carcinoma associated antibodies such as anti-EGP-2, CEA, CSAP, MUC1-4, EGFR, HER2/neu, PSA, CC49 (anti-Tag 72 antibody) and PSMA antibodies. These



solid tumor antibodies may be naked or conjugated to, *inter alia*, drugs, enzymes, hormones, toxins, isotopes, or immunomodulators. A fusion protein of a humanized, chimeric or fully human RS7 antibody and a toxin or may also be used in this invention. Many different antibody combinations may be constructed, either as naked antibodies or as partly naked and partly conjugated with a therapeutic agent or immunomodulator. Alternatively, different naked antibody combinations may be employed for administration in combination with other therapeutic agents, such as a cytotoxic drug or with radiation. Combinations of such antibodies can also be made, advantageously, with antisense oligonucleotides, as are known in the art. As such, the therapeutic conjugates may comprise an oligonucleotide, especially an antisense oligonucleotide that preferably are directed against oncogenes and oncogene products of B-cell malignancies. For example, antisense molecules inhibiting bcl-2 expression that are described in U.S. 5,734,033 (Reed) which is incorporated by reference in its entirety, may also be conjugated to, or form the therapeutic agent portion of an antibody fusion protein or be administered with a humanized RS7 antibody of the present invention.

The monospecific binding proteins described herein that are linked to diagnostic or therapeutic agents directly target RS7 positive tumors. The monospecific molecules bind selectively to targeted antigens and as the number of binding sites on the molecule increases, the affinity for the target cell increases and a longer residence time is observed at the desired location. Moreover, non-antigen bound molecules are cleared from the body quickly and exposure of normal tissues is minimized. A use of multispecific binding proteins is pre-targeting RS7 positive tumors for subsequent specific delivery of diagnostic or therapeutic agents. The agents are carried by histamine succinyl glycyl (HSG) containing peptides. The murine monoclonal antibody designated 679 (an IgG1, K) binds with high affinity to molecules containing the tri-peptide moiety, HSG (Morel *et al*, Molecular immunology, 27, 995-1000, 1990). 679 MAb can form a bispecific binding protein with hRS7 that binds with HSG and the target antigen. Alternative haptens may also be utilized. These binding proteins bind selectively to targeted antigens allowing for increased affinity and a longer residence time at the desired location. Moreover, non-

antigen bound diabodies are cleared from the body quickly and exposure of normal tissues is minimized.

RS7 antibodies and fragments thereof can be used to treat mammalian disorders such as cancer. The cancer includes, but is not limited to, lung, breast, bladder, ovarian prostate and colon cancers.

Delivering a diagnostic or a therapeutic agent to a target for diagnosis or treatment in accordance with the invention includes providing the anti-EGP-1 antibody or fragments thereof with a diagnostic or therapeutic agent and administering to a subject in need thereof with the binding protein. Diagnosis further requires the step of detecting the bound proteins with known techniques.

Administration of the antibodies and their fragments of the present invention with diagnostic or therapeutic agents can be effected in a mammal by intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, perfusion through a regional catheter, or direct intralesional injection. When administering the binding protein by injection, the administration may be by continuous infusion or by single or multiple boluses. Doses in the range of 20 to 800 mg/m<sup>2</sup> are feasible, with doses between 100 and 500 mg/m<sup>2</sup> preferably, for therapy, and commensurately lower doses recommended for diagnostic imaging, such as 0.5 mg to 100 mg/patient. Such doses may be repeated at different frequencies, depending on the clinical situation and patient tolerance.

The antibody with the diagnostic or therapeutic agent may be provided as a kit for human or mammalian therapeutic and diagnostic use in a pharmaceutically acceptable injection vehicle, preferably phosphate-buffered saline (PBS) at physiological pH and concentration. The preparation preferably will be sterile, especially if it is intended for use in humans. Optional components of such kits include stabilizers, buffers, labeling reagents, radioisotopes, paramagnetic compounds, second antibody for enhanced clearance, and conventional syringes, columns, vials and the like.

#### Naked antibody therapy

A therapeutically effective amount of the naked chimeric, humanized and fully human RS7 antibodies, or their fragments, can be formulated in a pharmaceutically

acceptable excipient. The efficacy of the naked chimeric, humanized and fully human RS7 antibodies can also be enhanced by supplementing these naked antibodies with one or more other naked antibodies, with one or more immunoconjugates of chimeric, humanized and fully human RS7 antibodies conjugated to a therapeutic agent, such as a drug, toxin, immunomodulator, hormone, growth factor, enzyme or therapeutic radionuclides, or with one or more therapeutic agent, including a drug, toxin, immunomodulator, hormone, growth factor, enzyme, oligonucleotide, or therapeutic radionuclide, administered concurrently or sequentially or according to a prescribed dosing regimen, with the RS7 antibodies or fragments thereof.

In a preferred embodiment, the naked or conjugated RS7 antibodies of the present invention are combined with at least one cancer drug. Such combination therapy can improve the effect of the drug or lower drug dose that is needed. For example, the  $IC_{50}$  value was determined for Dox-RS7 and 2P-Dox-RS7 on a lung cancer cell line, Calu3, and two breast cancer cell lines, MDA468 and T47D, respectively. Calu3 and T47D cells are positive for an EGP-1 antigen and negative for a CEA antigen, and MDA468 is positive for both the EGP-1 and CEA antigens. Results indicate that the  $IC_{50}$  value for Dox-RS7 is 0.04  $\mu\text{g/ml}$  and for 2P-Dox-RS7 is 0.023  $\mu\text{g/ml}$ . Therefore, conjugating a naked, human, humanized or chimeric anti-EGP-1 antibody or fragment of the present invention to a particular drug, such as 2P-Dox may help overcome multidrug resistance. This is also possible when the antibody is given in a combination with a particular drug, as described.

#### RS7 immunoconjugates

The present invention also contemplates the use of humanized, chimeric and human RS7 antibodies and fragments thereof for therapy. The objective of immunotherapy is to deliver cytotoxic doses of radioactivity, toxin, cytokine, enzyme, or hormone, or drug to target cells, while minimizing exposure to non-target tissues. The RS7 antigen binding proteins of the present invention can be used to treat a variety of tumors, such as of the lung, breast, bladder, ovary, uterus, stomach, and prostate.

Any of the antibodies or antibody fusion proteins and fragments thereof of the present invention can be conjugated with one or more therapeutic or diagnostic agents.

Generally, one therapeutic or diagnostic agent is attached to each antibody or antibody fragment but more than one therapeutic agent or diagnostic agent can be attached to the same antibody or antibody fragment. If the Fc region is absent (for example when the antibody used as the antibody component of the immunoconjugate is an antibody fragment), it is possible to introduce a carbohydrate moiety into the light chain variable region of a full-length antibody or antibody fragment. See, for example, Leung *et al.*, *J. Immunol.* 154: 5919 (1995); Hansen *et al.*, U.S. Patent No. 5,443,953 (1995), Leung *et al.*, U.S. patent No. 6,254,868, all of which are incorporated in their entirety by reference. The engineered carbohydrate moiety is used to attach the therapeutic or diagnostic agent.

Methods for conjugating peptides to antibody components via an antibody carbohydrate moiety are well-known to those of skill in the art. See, for example, Shih *et al.*, *Int. J. Cancer* 41: 832 (1988); Shih *et al.*, *Int. J. Cancer* 46: 1101 (1990); and Shih *et al.*, U.S. Patent No. 5,057,313, all of which are incorporated in their entirety by reference. The general method involves reacting an antibody component having an oxidized carbohydrate portion with a carrier polymer that has at least one free amine function and that is loaded with a plurality of peptide. This reaction results in an initial Schiff base (imine) linkage, which can be stabilized by reduction to a secondary amine to form the final conjugate. Also, a chelator such as DTPA (such as Mx-DTPA), DOTA, TETA, or NOTA can be attached to the antibody.

The antibody fusion proteins of the present invention comprise two or more antibodies or fragments thereof and each of the antibodies or fragments that compose this fusion protein can contain a therapeutic agent or diagnostic agent. Additionally, one or more of the antibodies or fragments of the antibody fusion protein can have more than one therapeutic or diagnostic agent attached. Further, the therapeutic agents do not need to be the same but can be different therapeutic agents, for example, one can attach a drug and a radioisotope to the same fusion protein. Particularly, an IgG can be radiolabeled with  $^{131}\text{I}$  and attached to a drug. The  $^{131}\text{I}$  can be incorporated into the tyrosine of the IgG and the drug attached to the epsilon amino group of the IgG lysines. Both therapeutic and diagnostic agents also can be attached to reduced SH groups and to the carbohydrate side chains.

A wide variety of diagnostic and therapeutic reagents can be advantageously conjugated to the antibodies of the invention. The therapeutic agents recited here are those agents that also are useful for administration separately with the naked antibody as described above. Therapeutic agents include, for example, chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxinw, taxanes, antimetabolites, alkylating agents, antibiotics, substituted urea, enzymes, Cox-2 inhibitors, antimitotics, antiangiogenic and apoptotic agents, particularly doxorubicin, doxorubicin analogs, methotrexate, taxol, CPT-11, camptothecans, and others from these and other classes of anticancer agents, methyl hydrazine derivative, adrenocortical suppressant, antagonist, endostatin, taxol, and the like. Other useful cancer chemotherapeutic drugs for the preparation of immunoconjugates and antibody fusion proteins include nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, COX-2 inhibitors, pyrimidine analogs, purine analogs, platinum coordination complexes, hormones, tyrosine kinase inhibitors, such as those that inhibit a EGF-receptor tyrosine kinase, a BCR ABL tyrosine kinase or a VEGF-receptor tyrosine kinase, and the like. Suitable chemotherapeutic agents are described in REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (Mack Publishing Co. 1995), and in GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7th Ed. (MacMillan Publishing Co. 1985), as well as revised editions of these publications. Other suitable chemotherapeutic agents, such as experimental drugs, are known to those of skill in the art.

A toxin, such as *Pseudomonas* exotoxin, may also be complexed to or form the therapeutic agent portion of an immunoconjugate of the RS7 and hRS7 antibodies of the present invention. Other toxins suitably employed in the preparation of such conjugates or other fusion proteins, include ricin, abrin, ribonuclease (RNase), DNase I, *Staphylococcal* enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, *Pseudomonas* exotoxin, and *Pseudomonas* endotoxin. See, for example, Pastan *et al.*, *Cell* 47:641 (1986), and Goldenberg, *CA - A Cancer Journal for Clinicians* 44:43 (1994). Additional toxins suitable for use in the present invention are known to those of skill in

the art and are disclosed in U.S. Patent 6,077,499, which is incorporated in its entirety by reference.

An immunomodulator, such as a cytokine may also be conjugated to, or form the therapeutic agent portion of the EGP-1, RS7 and hRS7 immunoconjugate, or be administered unconjugated to the chimeric, humanized or human RS7 antibodies or fragments thereof of the present invention. As used herein, the term "immunomodulator" includes cytokines, stem cell growth factors, lymphotoxins, such as tumor necrosis factor (TNF), and hematopoietic factors, such as interleukins (*e.g.*, interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, and IL-21), colony stimulating factors (*e.g.*, granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF)), interferons (*e.g.*, interferons- $\alpha$ , - $\beta$  and - $\gamma$ ), the stem cell growth factor designated "S1 factor," erythropoietin and thrombopoietin, or a combination thereof. Examples of suitable immunomodulator moieties include IL-2, IL-6, IL-10, IL-12, IL-18, IL-21, interferon- $\gamma$ , TNF- $\alpha$ , and the like. Alternatively, subjects can receive naked EGP-1 or RS7 antibodies and a separately administered cytokine, which can be administered before, concurrently or after administration of the naked RS7 antibodies. The RS7 antibody may also be conjugated to the immunomodulator. The immunomodulator may also be conjugated to a hybrid antibody consisting of one or more antibodies binding to different antigens.

A therapeutic or diagnostic agent can be attached at the hinge region of a reduced antibody component via disulfide bond formation. As an alternative, such peptides can be attached to the antibody component using a heterobifunctional cross-linker, such as *N*-succinyl 3-(2-pyridyldithio)propionate (SPDP). Yu *et al.*, *Int. J. Cancer* 56: 244 (1994). General techniques for such conjugation are well-known in the art. See, for example, Wong, CHEMISTRY OF PROTEIN CONJUGATION AND CROSS-LINKING (CRC Press 1991); Upešlaciš *et al.*, "Modification of Antibodies by Chemical Methods," in MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, Birch *et al.* (eds.), pages 187-230 (Wiley-Liss, Inc. 1995); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies," in MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, Ritter *et al.* (eds.),

pages 60-84 (Cambridge University Press 1995). Alternatively, the therapeutic or diagnostic agent can be conjugated via a carbohydrate moiety in the Fc region of the antibody. The carbohydrate group can be used to increase the loading of the same peptide that is bound to a thiol group, or the carbohydrate moiety can be used to bind a different peptide.

Furthermore, a radiolabeled antibody, immunoconjugate, or fragments thereof may comprise a  $\gamma$ -emitting radioisotope or a positron-emitter useful for diagnostic imaging. Suitable radioisotopes, particularly in the energy range of 25 to 4,000 keV, include  $^{131}\text{I}$ ,  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{86}\text{Y}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{94\text{m}}\text{Tc}$ ,  $^{18}\text{F}$ ,  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{O}$ ,  $^{75}\text{Br}$ , and the like. See for example, U.S. Patent Application entitled "Labeling Targeting Agents with Gallium-68"- Inventors G.L.Griffiths and W.J. McBride, (U.S. Provisional Application No. 60/342,104), which discloses positron emitters, such as  $^{18}\text{F}$ ,  $^{68}\text{Ga}$ ,  $^{94\text{m}}\text{Tc}$  and the like, for imaging purposes and which is incorporated in its entirety by reference. Preferably, the energy range for diagnostic and therapeutic radionuclides is 25-4,000 keV. Other useful radionuclides include  $^{90}\text{Y}$ ,  $^{111}\text{In}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{189}\text{Re}$ ,  $^{177}\text{Lu}$ ,  $^{67}\text{Cu}$ ,  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{198}\text{Au}$ ,  $^{224}\text{Ac}$ ,  $^{126}\text{I}$ ,  $^{133}\text{I}$ ,  $^{77}\text{Br}$ ,  $^{113\text{m}}\text{In}$ ,  $^{95}\text{Ru}$ ,  $^{97}\text{Ru}$ ,  $^{103}\text{Ru}$ ,  $^{105}\text{Ru}$ ,  $^{107}\text{Hg}$ ,  $^{203}\text{Hg}$ ,  $^{94\text{m}}\text{Tc}$ ,  $^{121\text{m}}\text{Te}$ ,  $^{122\text{m}}\text{Te}$ ,  $^{125\text{m}}\text{Te}$ ,  $^{165}\text{Tm}$ ,  $^{167}\text{Tm}$ ,  $^{168}\text{Tm}$ ,  $^{111}\text{Ag}$ ,  $^{197}\text{Pt}$ ,  $^{109}\text{Pd}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{47}\text{Sc}$ ,  $^{153}\text{Sm}$ ,  $^{177}\text{Lu}$ ,  $^{105}\text{Rh}$ ,  $^{142}\text{Pr}$ ,  $^{143}\text{Pr}$ ,  $^{161}\text{Tb}$ ,  $^{166}\text{Ho}$ ,  $^{199}\text{Au}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{51}\text{Cr}$ ,  $^{59}\text{Fe}$ ,  $^{18}\text{F}$ ,  $^{75}\text{Se}$ ,  $^{201}\text{Tl}$ ,  $^{225}\text{Ac}$ ,  $^{76}\text{Br}$ ,  $^{86}\text{Y}$ ,  $^{169}\text{Yb}$ ,  $^{166}\text{Dy}$ ,  $^{212}\text{Pb}$ , and  $^{223}\text{Ra}$ .

For example,  $^{67}\text{Cu}$ , considered one of the more promising radioisotopes for radioimmunotherapy due to its 61.5 hour half-life and abundant supply of beta particles and gamma rays, can be conjugated to an RS7 antigen binding protein using the chelating agent, p-bromoacetamido-benzyl- tetraethylaminetetraacetic acid (TETA). Chase, *supra*. Alternatively,  $^{90}\text{Y}$ , which emits an energetic beta particle, can be coupled to an RS7 antigen binding protein using diethylenetriaminepentaacetic acid (DTPA). Moreover, a method for the direct radiolabeling of the RS7 MAb with  $^{131}\text{I}$  is described by Stein *et al.* (1991), *supra*, and the patent by Govindan *et al.*, WO 9911294A1 entitled "Stable Radioiodine Conjugates and Methods for Their Synthesis," and is incorporated herein by reference in their entirety.

The RS7 antibodies or fragments thereof of the present invention that have a boron addend-loaded carrier for thermal neutron activation therapy will normally be effected in similar ways. However, it will be advantageous to wait until non-targeted RS7 immunoconjugate clears before neutron irradiation is performed. Clearance can be accelerated using an antibody that binds to the RS7 antibody. See U.S. patent No. 4,624,846 for a description of this general principle. For example, boron addends such as carboranes, can be attached to RS7 antibodies. Carboranes can be prepared with carboxyl functions on pendant side chains, as is well-known in the art. Attachment of carboranes to a carrier, such as aminodextran, can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier. The intermediate conjugate is then conjugated to the RS7 antibody. After administration of the RS7 antibody conjugate, a boron addend is activated by thermal neutron irradiation and converted to radioactive atoms that decay by  $\alpha$ -emission to produce highly toxic, short-range effects.

Furthermore, the present invention includes methods of diagnosing cancer in a subject. Diagnosis may be accomplished by administering a diagnostically effective amount of a diagnostic conjugate, formulated in a pharmaceutically suitable excipient, and detecting said label. For example, radioactive and non-radioactive agents can be used as diagnostic agents. A suitable non-radioactive diagnostic agent is a contrast agent suitable for magnetic resonance imaging, computed tomography or ultrasound. Magnetic imaging agents include, for example, non-radioactive metals, such as manganese, iron and gadolinium, complexed with metal-chelate combinations that include 2-benzyl-DTPA and its monomethyl and cyclohexyl analogs, when used along with the antibodies of the invention. See U.S. Serial No. 09/921,290 filed on October 10, 2001, which is incorporated in its entirety by reference.

Accordingly, a method of diagnosing a malignancy in a subject is described, comprising (i) performing an *in vitro* diagnosis assay on a specimen from the subject with a composition comprising a naked anti-EGP-1 MAb or fragment thereof or a naked antibody fusion protein or fragment thereof. For example, RT-PCR and immunoassay *in vitro* diagnosis methods can be used to detect the presence of minute amounts of EGP-1 in



tissues, blood and other body fluids as a useful diagnostic/detection method.

Immunohistochemistry can be used to detect the presence of EGP-1 in a cell or tissue.

Preferably, the malignancy that is being diagnosed is a cancer. Most preferably, the cancer is selected from the group of lung, prostate, ovarian, breast, colon and bladder.

Additionally, a chelator such as DTPA, DOTA, TETA, or NOTA or a suitable peptide, to which a detectable label, such as a fluorescent molecule, or cytotoxic agent, such as a heavy metal or radionuclide, can be conjugated. For example, a therapeutically useful immunoconjugate can be obtained by conjugating a photoactive agent or dye to an antibody fusion protein. Fluorescent compositions, such as fluorochrome, and other chromogens, or dyes, such as porphyrins sensitive to visible light, have been used to detect and to treat lesions by directing the suitable light to the lesion. In therapy, this has been termed photoradiation, phototherapy, or photodynamic therapy (Jori *et al.* (eds.), *PHOTODYNAMIC THERAPY OF TUMORS AND OTHER DISEASES* (Libreria Progetto 1985); van den Bergh, *Chem. Britain* 22:430 (1986)). Moreover, monoclonal antibodies have been coupled with photoactivated dyes for achieving phototherapy. Mew *et al.*, *J. Immunol.* 130:1473 (1983); *idem.*, *Cancer Res.* 45:4380 (1985); Oseroff *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8744 (1986); *idem.*, *Photochem. Photobiol.* 46:83 (1987); Hasan *et al.*, *Prog. Clin. Biol. Res.* 288:471 (1989); Tatsuta *et al.*, *Lasers Surg. Med.* 9:422 (1989); Pelegrin *et al.*, *Cancer* 67:2529 (1991). However, these earlier studies did not include use of endoscopic therapy applications, especially with the use of antibody fragments or subfragments. Thus, the present invention contemplates the therapeutic use of immunoconjugates comprising photoactive agents or dyes.

Contrast agents such as a MRI contrast agent, a paramagnetic ion and an ultrasound enhancing agent are also contemplated in the present invention. For example, gadolinium ions, lanthanum ions, manganese ions or other comparable label, CT contrast agents, and ultrasound contrast agents are suitable for use in the present invention. In a preferred embodiment, the ultrasound enhancing agent is a liposome that comprises a humanized RS7 IgG or fragment thereof. Also preferred, the liposome is gas filled.

For purposes of therapy, the RS7 antibodies and fragments thereof of the present invention are administered to a patient in a therapeutically effective amount. An antibody is said to be administered in a “therapeutically effective amount” if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.

#### *In vitro* diagnosis

The present invention contemplates the use of RS7 antibodies, including RS7 and hRS7 antibodies and fragments thereof, to screen biological samples *in vitro* for the presence of the RS7 antigen. In such immunoassays, the RS7 antibody may be utilized in liquid phase or bound to a solid-phase carrier, as described below. Also, see Stein *et al.* (1993), *supra*, and Stein *et al.*, *Cancer Res.* 49: 32 (1989), which is fully incorporated by reference.

One example of a screening method for determining whether a biological sample contains the RS7 antigen is the radioimmunoassay (RIA). For example, in one form of RIA, the substance under test is mixed with RS7 antigen MAb in the presence of radiolabeled RS7 antigen. In this method, the concentration of the test substance will be inversely proportional to the amount of labeled RS7 antigen bound to the MAb and directly related to the amount of free labeled RS7 antigen. Other suitable screening methods will be readily apparent to those of skill in the art.

Alternatively, *in vitro* assays can be performed in which an RS7 antigen binding protein is bound to a solid-phase carrier. For example, MAbs can be attached to a polymer, such as aminodextran, in order to link the MAb to an insoluble support such as a polymer-coated bead, a plate or a tube.

Other suitable *in vitro* assays will be readily apparent to those of skill in the art. The specific concentrations of detectably labeled RS7 antigen binding protein and RS7 antigen, the temperature and time of incubation, as well as other assay conditions may be varied, depending on various factors including the concentration of the RS7 antigen in the sample, the nature of the sample, and the like. The binding activity of a sample of RS7 antigen binding protein may be determined according to well known methods. Those

skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

The presence of the RS7 antigen in a biological sample can be determined using an enzyme-linked immunosorbent assay (ELISA). In the direct competitive ELISA, a pure or semipure antigen preparation is bound to a solid support that is insoluble in the fluid or cellular extract being tested and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the binary complex formed between solid-phase antigen and labeled antibody.

In contrast, a "double-determinant" ELISA, also known as a "two-site ELISA" or "sandwich assay," requires small amounts of antigen and the assay does not require extensive purification of the antigen. Thus, the double-determinant ELISA is preferred to the direct competitive ELISA for the detection of an antigen in a clinical sample. See, for *example*, the use of the double-determinant ELISA for quantitation of the *c-myc* oncoprotein in biopsy specimens. Field *et al.*, *Oncogene* 4: 1463 (1989); Spandidos *et al.*, *AntiCancer Res.* 9: 821 (1989).

In a double-determinant ELISA, a quantity of unlabeled MAb or antibody fragment (the "capture antibody") is bound to a solid support, the test sample is brought into contact with the capture antibody, and a quantity of detectably labeled soluble antibody (or antibody fragment) is added to permit detection and/or quantitation of the ternary complex formed between the capture antibody, antigen, and labeled antibody. An antibody fragment is a portion of an antibody such as  $F(ab')_2$ ,  $F(ab)_2$ ,  $Fab'$ ,  $Fab$ , and the like. In the present context, an antibody fragment is a portion of an RS7 MAb that binds to an epitope of the RS7 antigen. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, and recombinant single chain polypeptide

molecules in which light and heavy variable regions are connected by a peptide linker. An antibody fusion protein is a polyspecific antibody composition comprising at least two substantially monospecific antibodies or antibody fragments, wherein at least two of the antibodies or antibody fragments bind to different epitopes of the RS7 antigen. An RS7 fusion protein also includes a conjugate of an antibody fusion protein with a diagnostic or therapeutic agent. The term RS7 antibody includes humanized, chimeric, human and murine antibodies, antibody fragments thereof, immunoconjugates and fragments thereof and antibody fusion proteins and fragments thereof.

Methods of performing a double-determinant ELISA are well-known. See, for example, Field *et al.*, *supra*, Spandidos *et al.*, *supra*, and Moore *et al.*, "Twin-Site ELISAs for *fos* and *myc* Oncoproteins Using the AMPAK System," in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 273-281 (The Humana Press, Inc. 1992). For example, in one method for the detection of RS7 antigen using the double-determinant ELISA, finely minced tissue from a biopsy sample is lyophilized and resuspended in lysis buffer (100 mM NaCl, 50 mM Tris-HCl, pH 7.4) containing 1% nonidet-p40 (NP40), 0.6 µl/ml aprotinin, 0.2 mM phenyl methyl sulphonyl fluoride, 0.1 µg/ml leupeptin and 1 mM EDTA at a concentration of 10-20 mg tissue (wet weight) per 500 µl solution. The suspension is incubated for 60 minutes on ice, and then sonicated for approximately six 10-second intervals. Insoluble material is removed by centrifugation.

The soluble extract is added to microtiter plate wells containing an adsorbed RS7 antigen MAb as the capture antibody. Captured RS7 antigen is then recognized by a second RS7 antigen MAb, which has been coupled with alkaline phosphatase. The amount of bound alkaline phosphatase, proportional to the amount of RS7 antigen in the extract, is detected colorimetrically using a chromogenic substrate, such as *p*-nitrophenylphosphate.

Alternatively, a double-determinant ELISA for the RS7 antigen can be performed using horse radish peroxidase. Other variations of sample preparation and the double-

determinant ELISA can be devised by those of skill in the art with routine experimentation.

In the double-determinant ELISA, the soluble antibody or antibody fragment must bind to an RS7 epitope that is distinct from the epitope recognized by the capture antibody. For example, the soluble antibody can be the RS7 MAb, while the capture antibody can be MR23. Alternatively, the soluble antibody can be MR23, while the capture antibody can be the RS7 MAb.

The double-determinant ELISA can be performed to ascertain whether the RS7 antigen is present in a biopsy sample. Alternatively, the assay can be performed to quantitate the amount of RS7 antigen that is present in a clinical sample of body fluid. The quantitative assay can be performed by including dilutions of purified RS7 antigen. A method for purifying the RS7 antigen is illustrated below.

The RS7 MAbs and fragments thereof of the present invention also are suited for the preparation of an assay kit. Such a kit may comprise a carrier means that is compartmentalized to receive in close confinement one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the immunoassay.

For example, there may be a container means containing the capture antibody immobilized on a solid phase support, and a further container means containing detectably labeled antibodies in solution. Further container means may contain standard solutions comprising serial dilutions of RS7 antigen. The standard solutions of RS7 antigen may be used to prepare a standard curve with the concentration of RS7 antigen plotted on the abscissa and the detection signal on the ordinate. The results obtained from a sample containing RS7 antigen may be interpolated from such a plot to give the concentration of RS7 antigen in the biological sample.

RS7 antibodies and their fragments of the present invention also can be used to detect the presence of the RS7 antigen in tissue sections prepared from a histological specimen. Such *in situ* detection can be used to determine the presence of the RS7 antigen and to determine the distribution of the RS7 antigen in the examined tissue. *In*

*situ* detection can be accomplished by applying a detectably-labeled RS7 antigen binding protein to frozen tissue sections. Studies indicate that the RS7 antigen is not preserved in paraffin-embedded sections. Stein *et al.* (1993), *supra*. General techniques of *in situ* detection are well-known to those of ordinary skill. See, for example, Ponder, "Cell Marking Techniques and Their Application," in MAMMALIAN DEVELOPMENT: A PRACTICAL APPROACH 113-38 Monk (ed.) (IRL Press 1987), and Coligan at pages 5.8.1-5.8.8. Also, see Stein *et al.* (1989), *supra*, and Stein *et al.* (1993), *supra*.

RS7 antibodies and their fragments can be detectably labeled with any appropriate detection agent, for example, a radioisotope, an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent labels or a paramagnetic label. Methods of making and detecting such detectably-labeled RS7 antigen binding proteins are well-known to those of ordinary skill in the art, and are described in more detail below.

The marker moiety can be a radioisotope that is detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. In a preferred embodiment, the diagnostic conjugate is a gamma-, beta- or a positron-emitting isotope. A marker moiety in the present description refers to molecule that will generate a signal under predetermined conditions. Examples of marker moieties include radioisotopes, enzymes, fluorescent labels, chemiluminescent labels, bioluminescent labels and paramagnetic labels. As used herein, a diagnostic or therapeutic agent is a molecule or atom which is conjugated to an antibody moiety to produce a conjugate which is useful for diagnosis and for therapy. Examples of diagnostic or therapeutic agents include drugs, toxins, chelators, dyes, chromagens, boron compounds, and marker moieties. Isotopes that are particularly useful for the purpose of the present invention are  $^3\text{H}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , and preferably  $^{125}\text{I}$ . Examples of other radionuclides are, for example,  $^{90}\text{Y}$ ,  $^{111}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{177}\text{Lu}$ ,  $^{67}\text{Cu}$ ,  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ , and  $^{211}\text{At}$ . Additional radionuclides are also available as diagnostic and therapeutic agents. Suitable diagnostic imaging isotopes are usually in the range of 25 to 4,000 keV, while suitable therapeutic radionuclides are usually in the range of 60 to 700 keV.

The RS7 antibodies and their fragments of the present invention also can be labeled with a fluorescent compound. The presence of a fluorescently-labeled MAb is determined by exposing the RS7 antigen binding protein to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, *o*-phthalaldehyde and fluorescamine. Fluorescently-labeled RS7 antigen binding proteins are particularly useful for flow cytometry analysis.

Alternatively, RS7 antibodies and their fragments can be detectably labeled by coupling the RS7 antigen binding protein to a chemiluminescent compound. The presence of the chemiluminescent-tagged MAb is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.

Similarly, a bioluminescent compound can be used to label RS7 antibodies and fragments thereof of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Bioluminescent compounds that are useful for labeling include luciferin, luciferase and aequorin.

Alternatively, RS7 antibodies and fragments thereof can be detectably labeled by linking the RS7 antibody to an enzyme. When the RS7 antibody-enzyme conjugate is incubated in the presence of the appropriate substrate, the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to detectably label RS7 antibody include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase,  $\alpha$ -glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase,  $\beta$ -galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.

RS7 antibodies, fusion proteins, and fragments thereof also can be labeled with paramagnetic ions for purposes of *in vivo* diagnosis. Contrast agents that are particularly useful for magnetic resonance imaging comprise Gd, Mn, Dy or Fe ions. RS7 antibodies and fragments thereof can also be conjugated to ultrasound contrast/enhancing agents. For example, the ultrasound contrast agent is a liposome that comprises a humanized RS7 IgG or fragment thereof. Also preferred, the ultrasound contrast agent is a liposome that is gas filled.

In a related vein, a bispecific antibody can be conjugated to a contrast agent. For example, the bispecific antibody may comprise more than one image-enhancing agent for use in ultrasound imaging. In a preferred embodiment, the contrast agent is a liposome. Preferably, the liposome comprises a bivalent DTPA-peptide covalently attached to the outside surface of the liposome. Still preferred, the liposome is gas filled.

Those of skill in the art will know of other suitable labels that can be employed in accordance with the present invention. The binding of marker moieties to RS7 antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy *et al.*, *Clin. Chim. Acta* 70: 1 (1976), Schurs *et al.*, *Clin. Chim. Acta* 81: 1 (1977), Shih *et al.*, *Int'l J. Cancer* 46: 1101 (1990), Stein *et al.* (1990), *supra*, and Stein *et al.* (1993), *supra*. Also, see generally, Coligan.

The above-described *in vitro* and *in situ* detection methods may be used to assist in the diagnosis or staging of a pathological condition. For example, such methods can be used to detect tumors that express the RS7 antigen including tumors of the lung, breast, bladder, ovary, uterus, stomach, and prostate.

#### *In vivo* diagnosis

The present invention also contemplates the use of RS7 antibodies for *in vivo* diagnosis. The method of diagnostic imaging with radiolabeled MAbs is well-known. In the technique of immunoscintigraphy, for example, antibodies are labeled with a gamma-emitting radioisotope and introduced into a patient. A gamma camera is used to detect the location and distribution of gamma-emitting radioisotopes. See, for example, Srivastava (ed.), *RADIOLABELED MONOCLONAL ANTIBODIES FOR IMAGING*



AND THERAPY (Plenum Press 1988), Chase, "Medical Applications of Radioisotopes," in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition, Gennaro *et al.* (eds.), pp. 624-652 (Mack Publishing Co., 1990), and Brown, "Clinical Use of Monoclonal Antibodies," in BIOTECHNOLOGY AND PHARMACY 227-49, Pezzuto *et al.* (eds.) (Chapman & Hall 1993).

For diagnostic imaging, radioisotopes may be bound to the RS7 antibody either directly, or indirectly by using an intermediary functional group. Useful intermediary functional groups include chelators such as ethylenediaminetetraacetic acid and diethylenetriaminepentaacetic acid. For example, see Shih *et al.*, *supra*, and U.S. patent No. 5,057,313.

The radiation dose delivered to the patient is maintained at as low a level as possible through the choice of isotope for the best combination of minimum half-life, minimum retention in the body, and minimum quantity of isotope which will permit detection and accurate measurement. Examples of radioisotopes that can be bound to RS7 antibody and are appropriate for diagnostic imaging include  $^{99m}\text{Tc}$  and  $^{111}\text{In}$ .

#### **Pharmaceutically suitable excipient**

Additional pharmaceutical methods may be employed to control the duration of action of an RS7 antibody in a therapeutic application. Control release preparations can be prepared through the use of polymers to complex or adsorb the RS7 antibody. For example, biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood *et al.*, *Bio/Technology* 10: 1446 (1992). The rate of release of an RS7 antibody from such a matrix depends upon the molecular weight of the RS7 antibody, the amount of RS7 antibody within the matrix, and the size of dispersed particles. Saltzman *et al.*, *Biophys. J.* 55: 163 (1989); Sherwood *et al.*, *supra*. Other solid dosage forms are described in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed. (1990).

The humanized, chimeric and human RS7 antibodies to be delivered to a subject can consist of the antibody alone, immunoconjugate, fusion protein, or can comprise one

or more pharmaceutically suitable excipients, one or more additional ingredients, or some combination of these.

The immunoconjugate, naked antibody, fusion protein, and fragments thereof of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the immunoconjugate or naked antibody is combined in a mixture with a pharmaceutically suitable excipient. Sterile phosphate-buffered saline is one example of a pharmaceutically suitable excipient. Other suitable excipients are well-known to those in the art. See, for example, Ansel *et al.*, PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea & Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), and revised editions thereof.

The immunoconjugate or naked antibody of the present invention can be formulated for intravenous administration via, for example, bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

Additional pharmaceutical methods may be employed to control the duration of action of the therapeutic or diagnostic conjugate or naked antibody. Control release preparations can be prepared through the use of polymers to complex or adsorb the immunoconjugate or naked antibody. For example, biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood *et al.*, *Bio/Technology* 10: 1446 (1992). The rate of release of an immunoconjugate or antibody from such a matrix depends upon the molecular weight of the immunoconjugate or antibody, the amount of immunoconjugate, antibody within the matrix, and the size of dispersed particles. Saltzman *et al.*, *Biophys. J.* 55: 163 (1989); Sherwood *et al.*, *supra*. Other solid dosage

forms are described in Ansel *et al.*, PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea & Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), and revised editions thereof.

The immunoconjugate, antibody fusion protein, naked antibody, and fragments thereof may also be administered to a mammal subcutaneously or even by other parenteral routes. In a preferred embodiment, the anti-EGP-1 antibody or fragment thereof is administered in a dosage of 10 to 2000 milligrams protein per dose. Moreover, the administration may be by continuous infusion or by single or multiple boluses. In general, the dosage of an administered immunoconjugate, fusion protein or naked antibody for humans will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of immunoconjugate, antibody fusion protein or naked antibody that is in the range of from about 1 mg/kg to 20 mg/kg as a single intravenous infusion, although a lower or higher dosage also may be administered as circumstances dictate. This dosage may be repeated as needed, for example, once per week for 4-10 weeks, preferably once per week for 8 weeks, and more preferably, once per week for 4 weeks. It may also be given less frequently, such as every other week for several months. The dosage may be given through various parenteral routes, with appropriate adjustment of the dose and schedule.

The RS7 antibodies of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby RS7 antibodies are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Ed. (1990).

For purposes of therapy, the immunoconjugate, fusion protein, or naked antibody is administered to a mammal in a therapeutically effective amount. A suitable subject for

the present invention is usually a human, although a non-human animal subject is also contemplated. An antibody preparation is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient mammal.

It will be apparent to those skilled in the art that various modifications and variations can be made to the compositions and processes of this invention. Thus, it is intended that the present invention cover such modifications and variations, provided they come within the scope of the appended claims and their equivalents.

The disclosure of all publications, patents and patent applications cited above are expressly incorporated herein by reference in their entireties to the same extent as if each were incorporated by reference individually.

\* \* \*

The examples below are illustrative of embodiments of the current invention and should not be used, in any way, to limit the scope of the claims.

**Example 1. Construction of a chimeric RS7 antibody**

*Molecular cloning of RS7V $\kappa$  and VH genes*

Total cytoplasmic RNA and mRNA was prepared from RS7-producing hybridoma cells. The genes encoding V $\kappa$  and VH sequences were cloned by RT-PCR and 5'RACE and the sequences were determined by DNA sequencing. Multiple independent clones were sequenced to eliminate possible errors resulting from the PCR reaction. Sequence analyses revealed presence of two V $\kappa$  (#1 and #23) and one VH (RS7VH) transcripts. Combining each of the putative murine V $\kappa$  with the VH, two chimeric Abs (cAbs), containing human constant region domains were generated and expressed in Sp2/0 cells by transfection. cAb-producing clones were identified by screening the cell culture supernatants of the transfected cell clones by ELISA. Positive clones were expanded and cAbs were purified from the cell culture supernatants. The Ag-binding assay showed that only the cAb composed of V $\kappa$ #23 and VH, cAb-V $\kappa$ #23,

bound to microwells coated with the crude membrane fraction of ME180, a human cervical carcinoma cell (ATCC, Rockville, MD) (Figure 1). The cAb with the combination of V $\kappa$ #1 and V<sub>H</sub>, cAb-V $\kappa$ #1, did not show binding to the Ag-coated wells. Therefore, the immunoreactive cAb (with V $\kappa$ #23) was designated as cRS7. The cloned murine V<sub>H</sub> and the functional V $\kappa$  (#23) sequences as the final PCR products were designated as RS7V $\kappa$  (Figure 2A) and RS7V<sub>H</sub> (Figure 2B), respectively.

#### *Binding activity assay for RS7 Abs*

A competitive ELISA binding assay was used to evaluate the binding affinity of engineered cRS7. Briefly, constant amount of biotinylated murine RS7 is mixed with varying concentrations (0.01-100  $\mu$ g/ml) of testing Abs (RS7 or cRS7), and added into Ag-coated microwells, and incubated at room temperature for 1 h. After washing, HRP conjugated streptavidin is added and incubated for 1 h at room temperature. The amount of HRP-conjugated streptavidin bound to the Ag-bound biotinylated RS7 was revealed by reading OD<sub>490</sub> after the addition of a substrate solution containing 4 mM ortho-phenylenediamine dihydrochloride and 0.04% H<sub>2</sub>O<sub>2</sub>. By this type of competitive Ag-binding assay, it was revealed that cRS7 and murine RS7 competed equally well for the binding of biotinylated murine RS7 to the antigen coated wells, thus confirmed the authenticity of the V $\kappa$  and V<sub>H</sub> sequences obtained (Fig. 1).

#### **Example 2. Method of hRS7 antibody construction**

##### *Sequence design of hRS7 V genes*

By searching the human V $\kappa$  and V<sub>H</sub> sequences in the Kabat database, the FRs of RS7 V $\kappa$  and V<sub>H</sub> were found to exhibit the highest degree of sequence homology to human SA-1A'cl V $\kappa$  and RF-TS3 V<sub>H</sub>, respectively. One exception is the FR4 of RS7V<sub>H</sub>, which showed the highest sequence homology with that of NEWM V<sub>H</sub>. Therefore human SA-1A'CL framework sequences were used as the scaffold for grafting the CDRs of RS7V $\kappa$  (Figure 3A), and a combination of RF-TS3 and NEWM framework sequences were used for RS7V<sub>H</sub> (Figure 4). There are a number of amino acid changes in each chain outside of the CDR regions when compared to the starting human antibody

frameworks. Several amino acid residues in murine FRs that flank the putative CDRs were maintained in the reshaped hRS7 Fv based on the guideline previously established Qu,Z., Losman,M.J., Eliassen,K.C., Hansen,H.J., Goldenberg,D.M., and Leung,S.O. (1999). Humanization of Immu31, an alpha-fetoprotein-specific antibody. Clin. Cancer Res. 5, 3095s-3100s. These residues are S20, D60, V85, and A100 of RS7Vk and K38, K46, A78, and F91 of RS7VH (Figure 3A and 3B).

#### *Construction of hRS7 V sequences*

A modified strategy as described by Leung et al. Leung, S.O., Shevitz, J., Pellegrini, M.C., Dion, A.S., Shih, L.B., Goldenberg, D.M., and Hansen, H.J. (1994) Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma. Hybridoma, 13: 469-476) was used to construct the designed VL and VH genes for hRS7 using a combination of long oligonucleotide syntheses and PCR as illustrated in Figure 4. For the construction of the hRS7 VH domain, two long oligonucleotides, hRS7VHA (176-mer) and hRS7VHB (168-mer) were synthesized on an automated DNA synthesizer (Applied Biosystem).

hRS7VHA represents nt 23 to 198 of the hRS7VH domain

5'-GGTCTGAGTT GAAGAAGCCT GGGGCCTCAG TGAAGGTTTC  
CTGCAAGGCT TCTGGATACA CCTTCACAAA CTATGGAATG AACTGGGTGA  
AGCAGGCCCC TGGACAAGGG CTAAATGGA TGGGCTGGAT AAACACCTAC  
ACTGGAGAGC CAACATATAC TGATGACTTC AAGGGA-3'

hRS7VHB represents the minus strand of the hRS7VH domain complementary to nt 174 to 340.

5'-ACCCTTGGCC CCAGACATCG AAGTACCAGT AGCTACTACC  
GAACCCCCCT CTTGCACAGA AATACACGGC AGTGTCGTCA GCCTTTAGGC  
TGCTGATCTG GAGATATGCC GTGCTGACAG AGGTGTCCAA GGAGAAGGCA  
AACCGTCCCT TGAAGTCATC AGTATATG-3'

The 3'-terminal sequences (23 nt residues) of hRS7VHA and B are complementary to each other. Under defined PCR condition, 3'-ends of hRS7VHA and B anneal to form a short double stranded DNA flanked by the rest of the long

oligonucleotides. Each annealed end serves as a primer for the transcription of the single stranded DNA, resulting in a double strand DNA composed of the nt 23 to 340 of hRS7VH. This DNA was further amplified in the presence of two short oligonucleotides, hRS7VHBACK and hRS7VHFOR to form the full-length hRS7VH.

hRS7VHBACK      5'-GTGGTGCTGC AGCAATCTGG GTCTGAGTTG  
AAGAAGCC-3'

hRS7VHFOR        5'-TGAGGAGACG GTGACCAGGG ACCCTTGGCC  
CCAGACAT-3'

Minimum amount of hRS7VHA and B (determined empirically) was amplified in the presence of 10 µl of 10x PCR Buffer (500 mM KCl, 100 mM Tris.HCL buffer, pH 8.3, 15 mM MgCl<sub>2</sub>), 2 µmol of hRS7VHBACK and hRS7VHFOR, and 2.5 units of Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, Ct). This reaction mixture was subjected to 3 cycle of PCR reaction consisting of denaturation at 94°C for 1 minute, annealing at 45°C for 1 minute, and polymerization at 72°C for 1.5 minutes, and followed by 27 cycles of PCR reaction consisting of denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and polymerization at 72°C for 1 minute. Double-stranded PCR-amplified product for hRS7VH was gel-purified, restriction-digested with PstI and BstEII and cloned into the complementary PstI/BstEII sites of the heavy chain staging vector, VHpBS2.

For constructing the full length DNA of the humanized V $\kappa$  sequence, hRS7VKA (156-mer) and hRS7VKB (155-mer) were synthesized as described above. hRS7VKA and B were amplified by two short oligonucleotides hRS7VKBACK and hRS7VKFOR as described above.

HRS7VKA represents nt 20 to 175 of the hRS7V $\kappa$  domain.

5'-CTCCATCCTC CCTGTCTGCA TCTGTAGGAG ACAGAGTCAG CATCACCTGC  
AAGGCCAGTC AGGATGTGAG TATTGCTGTA GCCTGGTATC AGCAGAAACC  
AGGGAAAGCC CCTAAGCTCC TGATCTACTC GGCATCCTAC CCGTACACTG  
GAGTCC-3'

hRS7VKB represents the minus strand of the hRS7V $\kappa$  domain complementary to nt 155 to 320.

5'-CCTTGGTCCC AGCACCGAAC GTGAGCGGAG TAATATAATG  
TTGCTGACAG TAATAAACTG CAAAATCTTC AGGTTGCAGA CTGCTGATGG  
TGAGAGTGAA ATCTGTCCCA GATCCACTGC CACTGAACCT ATCAGGGACT  
CCAGTGTACC GGTA-3'

hRS7VKBACK      5'-GACATTCAGC TGACCCAGTC TCCATCCTCC  
CTGTCTG-3'

hRS7VKFOR      5'-ACGTTAGATC TCCACCTTGG TCCCAGCACC G-3'

Gel-purified PCR products for hRS7V $\kappa$  were restriction-digested with PvuII and BglIII and cloned into the complementary PvuI/BcII sites of the light chain staging vector, VKpBR2. The final expression vector hRS7pdHL2 was constructed by sequentially subcloning the XbaI-BamHI and XhoI/BamHI fragments of hRS7V $\kappa$  and VH, respectively, into pdHL2 as described above.

#### Transfection and Expression of hRS7 Antibodies

Approximately 30  $\mu$ g of the expression vectors for hRS7 were linearized by digestion with SalI and transfected into Sp2/0-Ag14 cells by electroporation (450V and 25  $\mu$ F). The transfected cells were plated into 96-well plates for 2 days and then selected for drug-resistance by adding MTX into the medium at a final concentration of 0.025  $\mu$ M. MTX-resistant colonies emerged in the wells 2-3 weeks. Supernatants from colonies surviving selection were screened for human Ab secretion by ELISA assay. Briefly, 100  $\mu$ l supernatants were added into the wells of a microtiter plate precoated with GAH-IgG, F(ab')<sub>2</sub> fragment-specific Ab and incubated for 1 h at room temperature. Unbound proteins were removed by washing three times with wash buffer (PBS containing 0.05% polysorbate 20). HRP-conjugated GAH-IgG, Fc fragment-specific Ab was added to the wells. Following an incubation of 1 h, the plate was washed. The bound HRP-conjugated Ab was revealed by reading A490nm after the addition of a substrate solution containing 4 mM



OPD and 0.04% H<sub>2</sub>O<sub>2</sub>. Positive cell clones were expanded and hRS7 IgG were purified from cell culture supernatant by affinity chromatography on a Protein A column.

*Binding Activity of the humanized RS7 antibody*

An ELISA competitive binding assay using ME180 cell membrane extract coated plate was used to assess the immunoreactivity of hRS7 as described (Stein et al., Int. J. Cancer 55:938-946(1993)). ME180 cell membrane fraction was prepared by sonication and centrifugation. The crude membrane extract was coated in 96-well flat bottomed PVC plate by centrifugation and fixed with 0.1% glutaraldehyde. Constant amount of the biotinylated murine RS7 mixed with varying concentrations of mRS7, cRS7 or hRS7 was added to the membrane coated wells and incubated at room temperature for 1-2 h. After washing, HRP-conjugated streptavidin was added and incubated for 1 h at room temperature. The amount of HRP-conjugated streptavidin bound to the membrane-bound biotinylated mRS7 was revealed by reading A<sub>490 nm</sub> after the addition of a substrate solution containing 4 mM ortho-phenylenediamine dihydrochloride and 0.04% H<sub>2</sub>O<sub>2</sub>. As shown by the competition assays in Figure 6, hRS7 IgG exhibited comparable binding activities with that of mRS7 and cRS7, confirming the binding affinity of RS7 was preserved in humanization.

**Example 3. Radioiodinations of humanized RS7 using residualizing labels**

The residualizing moiety (IMP-R4, IMP-R5 or IMP-R8) was radioiodinated, and coupled to disulfide-reduced hRS7 along the procedure described elsewhere (Govindan SV, et al. *Bioconjugate Chem.* 1999;10:231-240). See Figure 9. In residualizing radioiodine labelings using <sup>125</sup>I, to prepare <sup>125</sup>I-IMP-Rx-hRS7 where x = 4, 5 or 8), overall yields and specific activities (in parentheses) of 87.1 % (3.38 mCi/mg), 34.3 % (0.97 mCi/mg), and 76.6 % (2.93 mCi/mg) were obtained using IMP-R4, IMP-R5 and IMP-R8, respectively. In large-scale <sup>131</sup>I labelings using <sup>131</sup>I-IMP-R4 entity, the following results were obtained. Using 20.4 mCi of <sup>131</sup>I, 35.7 nmol of IMP-R4 and 3.22 mg of DTT-reduced hRS7, a 60 % overall yield (3.80 mCi/mg) was obtained. A different run using 30.3 mCi of <sup>131</sup>I, IMP-R4 and reduced hRS7 produced 69.7 % yield (3.88 mCi/mg). A third run using 13.97 mCi of <sup>131</sup>I gave 71.8 % incorporation (4.42 mCi/mg). A <sup>131</sup>I-

IMP-R4 labeling using 13.6 mCi of  $^{131}\text{I}$  and a non-specific humanized antibody, hLL2, resulted in 64.4 % yield (3.67 mCi/mg).

#### **Example 4. Preclinical experiments in breast cancer animal model**

For tumor targeting studies, tumors were propagated in 5-8 week old female nude mice by subcutaneous injection of  $\sim 2.3 \times 10^7$  cultured MDA-MB-468 cells, and the animals were used after one month when the tumor size reached  $\sim 0.1$ -to- $0.2 \text{ cm}^3$ . The mice were injected i.v. with a mixture of  $\sim 10 \text{ }\mu\text{Ci}$  of  $^{125}\text{I}$ -[IMP-Rx]-hRS7 where  $x = 4, 5$  or  $8$ , and  $20$ - $25 \text{ }\mu\text{Ci}$  of  $^{131}\text{I}$ -MAb (CT method). Thus, each experiment was a paired-label experiment with  $^{125}\text{I}/^{131}\text{I}$ . At the indicated times, biodistributions in various organs and blood were determined, and expressed as % injected dose per gram. Corrections for backscatter of  $^{131}\text{I}$  into  $^{125}\text{I}$  window were made in determining  $^{125}\text{I}$  biodistributions.

For therapy studies, tumor growth patterns under various formats were studied to determine the optimal method for steady growth of tumor. It was concluded that the method used for targeting experiments was optimal after about 8-weeks of tumor growth, and 30-50 % of the animals could be used based on the tumor growth profiles. For therapy studies, the tumor-bearing animals were injected i.v. with  $^{131}\text{I}$ -IMPR4-hRS7 was the agent examined, and compared with directly radioiodinated material,  $^{131}\text{I}$ -hRS7. Baseline body weights were compared with weekly measurements of body weights and tumor volumes. Animals were sacrificed when tumors reached  $3 \text{ cm}^3$ . All animal experiments were carried out in accord with IACUC-approved protocols.

#### *In vivo animal biodistributions*

These experiments were carried out using dual-labeled hRS7 preparations ( $^{125}\text{I}$ -IMP-Rx-hRS7 where  $x = 4, 5$  or  $8$ , with each agent mixed with direct label  $^{131}\text{I}$ -hRS7) in the tumors grown in NIH Swiss nude mice. Tables 1A, 1B and 1C describe detailed biodistributions showing the superior performance using the residualizing labels. For instance, % injected dose per gram of tumor on day-7 were  $41.6 \pm 3.0 \%$ ,  $32.2 \pm 11.6 \%$  and  $24.7 \pm 8.5 \%$  for  $^{125}\text{I}$ -IMP-R4-hRS7,  $^{125}\text{I}$ -IMP-R5-hRS7 and  $^{125}\text{I}$ -IMP-R8-hRS7, respectively, while that for directly labeled  $^{131}\text{I}$ -hRS7 at the same time-point in each of the dual-labeled experiments were  $5.9 \pm 0.9 \%$ ,  $6.2 \pm 2.1 \%$  and  $6.7 \pm 2.3 \%$ . Tumor-to-

nontumor ratios for the same time-point were 1.7-to-7.6-fold higher with  $^{125}\text{I}$ -IMP-R4-hRS7, 1.7-to-6.0-fold higher with  $^{125}\text{I}$ -IMP-R5-hRS7, and 2.0-to-4.8-fold higher with  $^{125}\text{I}$ -IMP-R8-hRS7 compared to the ratios with  $^{131}\text{I}$ -hRS7 (data not shown).

**Table-1. Biodistributions of humanized RS7, dual-labeled with  $^{125}\text{I}$ -IMP-R (R4 or R5 or R8) and  $^{131}\text{I}$ -hRS7 (CT method), in NIH Swiss nude mice bearing MDA-MB-468 tumor xenografts**

**Table 1A:  $^{125}\text{I}$ -IMP-R4-hRS7 versus  $^{131}\text{I}$ -hRS7 (CT)**

| Tissue     | Label                    | % ID/g $\pm$ SD <sup>1</sup> , n = 5 |                   |                   |                   |
|------------|--------------------------|--------------------------------------|-------------------|-------------------|-------------------|
|            |                          | 24 h                                 | 72 h              | 168 h, n = 4      | 336 h             |
| MDA-MB-468 | $^{125}\text{I}$ -IMP-R4 | 32.8 $\pm$ 6.3                       | 46.8 $\pm$ 11.0   | 41.6 $\pm$ 3.0    | 25.1 $\pm$ 3.8    |
|            | $^{131}\text{I}$ (CT)    | 8.6 $\pm$ 1.5                        | 8.6 $\pm$ 2.3     | 5.9 $\pm$ 0.9     | 4.4 $\pm$ 0.8     |
|            | Tumor wt.                | (0.19 $\pm$ 0.06)                    | (0.19 $\pm$ 0.08) | (0.13 $\pm$ 0.07) | (0.18 $\pm$ 0.04) |
| Liver      | $^{125}\text{I}$ -IMP-R4 | 5.7 $\pm$ 0.7                        | 4.7 $\pm$ 1.5     | 2.8 $\pm$ 0.4     | 1.3 $\pm$ 0.2     |
|            | $^{131}\text{I}$ (CT)    | 4.1 $\pm$ 0.3                        | 2.0 $\pm$ 0.1     | 1.5 $\pm$ 0.2     | 0.7 $\pm$ 0.1     |
| Spleen     | $^{125}\text{I}$ -IMP-R4 | 3.6 $\pm$ 0.6                        | 3.3 $\pm$ 0.6     | 2.6 $\pm$ 0.8     | 1.9 $\pm$ 0.2     |
|            | $^{131}\text{I}$ (CT)    | 2.6 $\pm$ 0.5                        | 1.7 $\pm$ 0.4     | 1.1 $\pm$ 0.4     | 0.6 $\pm$ 0.1     |
| Kidney     | $^{125}\text{I}$ -IMP-R4 | 7.8 $\pm$ 0.7                        | 6.8 $\pm$ 0.4     | 5.6 $\pm$ 0.8     | 3.0 $\pm$ 0.5     |
|            | $^{131}\text{I}$ (CT)    | 3.5 $\pm$ 0.3                        | 2.1 $\pm$ 0.3     | 1.4 $\pm$ 0.3     | 0.7 $\pm$ 0.1     |
| Lungs      | $^{125}\text{I}$ -IMP-R4 | 4.5 $\pm$ 1.0                        | 3.2 $\pm$ 0.6     | 2.2 $\pm$ 0.7     | 0.8 $\pm$ 0.2     |
|            | $^{131}\text{I}$ (CT)    | 3.1 $\pm$ 0.8                        | 2.2 $\pm$ 0.4     | 1.6 $\pm$ 0.6     | 0.6 $\pm$ 0.2     |
| Blood      | $^{125}\text{I}$ -IMP-R4 | 15.1 $\pm$ 1.4                       | 9.5 $\pm$ 0.7     | 6.0 $\pm$ 1.5     | 1.9 $\pm$ 0.6     |
|            | $^{131}\text{I}$ (CT)    | 10.8 $\pm$ 1.0                       | 7.3 $\pm$ 0.6     | 5.3 $\pm$ 1.2     | 2.2 $\pm$ 0.6     |
| Stomach    | $^{125}\text{I}$ -IMP-R4 | 1.3 $\pm$ 0.2                        | 0.6 $\pm$ 0.1     | 0.4 $\pm$ 0.1     | 0.2 $\pm$ 0.1     |
|            | $^{131}\text{I}$ (CT)    | 1.6 $\pm$ 0.5                        | 0.7 $\pm$ 0.1     | 0.4 $\pm$ 0.1     | 0.2 $\pm$ 0.1     |
| Sm. Int.   | $^{125}\text{I}$ -IMP-R4 | 1.5 $\pm$ 0.2                        | 0.9 $\pm$ 0.1     | 0.6 $\pm$ 0.2     | 0.2 $\pm$ 0.1     |
|            | $^{131}\text{I}$ (CT)    | 1.0 $\pm$ 0.1                        | 0.6 $\pm$ 0.1     | 0.4 $\pm$ 0.1     | 0.2 $\pm$ 0.04    |
| Lg. Int.   | $^{125}\text{I}$ -IMP-R4 | 1.3 $\pm$ 0.3                        | 1.0 $\pm$ 0.1     | 0.8 $\pm$ 0.1     | 0.3 $\pm$ 0.1     |
|            | $^{131}\text{I}$ (CT)    | 0.8 $\pm$ 0.2                        | 0.5 $\pm$ 0.1     | 0.5 $\pm$ 0.1     | 0.2 $\pm$ 0.03    |
| Muscle     | $^{125}\text{I}$ -IMP-R4 | 1.2 $\pm$ 0.2                        | 0.7 $\pm$ 0.1     | 0.5 $\pm$ 0.1     | 0.3 $\pm$ 0.2     |
|            | $^{131}\text{I}$ (CT)    | 0.9 $\pm$ 0.1                        | 0.5 $\pm$ 0.05    | 0.3 $\pm$ 0.1     | 0.2 $\pm$ 0.1     |
| Bone       | $^{125}\text{I}$ -IMP-R4 | 2.3 $\pm$ 0.3                        | 2.1 $\pm$ 0.3     | 2.4 $\pm$ 0.6     | 2.3 $\pm$ 1.2     |
|            | $^{131}\text{I}$ (CT)    | 1.4 $\pm$ 0.1                        | 0.8 $\pm$ 0.1     | 0.5 $\pm$ 0.1     | 0.3 $\pm$ 0.1     |

**Table-1B:  $^{125}\text{I}$ -IMP-R5-hRS7 versus  $^{131}\text{I}$ -hRS7 (CT method)**

| Tissue | Label                    | % ID/g $\pm$ SD <sup>1</sup> , n = 5 |                |                 |                |
|--------|--------------------------|--------------------------------------|----------------|-----------------|----------------|
|        |                          | 24 h                                 | 72 h           | 168 h           | 336 h, n = 4   |
| MDA-   | $^{125}\text{I}$ -IMP-R5 | 29.1 $\pm$ 4.6                       | 39.6 $\pm$ 2.7 | 32.2 $\pm$ 11.6 | 17.8 $\pm$ 7.0 |
|        | $^{131}\text{I}$ (CT)    | 9.2 $\pm$ 1.0                        | 9.1 $\pm$ 0.6  | 6.2 $\pm$ 2.1   | 4.9 $\pm$ 2.0  |

| MB-468   | Tumor wt.  | (0.14 ± 0.02)            | (0.20 ± 0.05)            | (0.11 ± 0.03)          | (0.13 ± 0.06)            |
|----------|--|--------------------------|--------------------------|------------------------|--------------------------|
| Liver    | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 4.8 ± 1.4<br>5.1 ± 1.5   | 2.5 ± 0.1<br>2.4 ± 0.2   | 1.8 ± 0.3<br>1.7 ± 0.2 | 0.8 ± 0.3<br>0.8 ± 0.3   |
| Spleen   | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 4.1 ± 1.0<br>3.8 ± 1.2   | 2.0 ± 0.4<br>1.7 ± 0.5   | 1.9 ± 0.4<br>1.3 ± 0.3 | 0.8 ± 0.4<br>0.7 ± 0.4   |
| Kidney   | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 10.0 ± 1.4<br>3.7 ± 0.5  | 6.3 ± 0.5<br>1.9 ± 0.3   | 5.0 ± 0.5<br>1.7 ± 0.3 | 1.1 ± 0.3<br>0.8 ± 0.2   |
| Lungs    | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 5.4 ± 1.8<br>3.9 ± 1.2   | 3.2 ± 0.8<br>2.5 ± 0.7   | 2.3 ± 0.2<br>2.0 ± 0.3 | 0.9 ± 0.4<br>0.9 ± 0.5   |
| Blood    | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 16.5 ± 4.0<br>12.2 ± 3.0 | 8.8 ± 0.6<br>7.8 ± 0.5   | 6.5 ± 1.0<br>6.3 ± 0.8 | 2.7 ± 1.4<br>3.1 ± 1.4   |
| Stomach  | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 0.9 ± 0.2<br>1.1 ± 0.1   | 0.5 ± 0.1<br>0.6 ± 0.1   | 0.4 ± 0.1<br>0.5 ± 0.1 | 0.2 ± 0.1<br>0.2 ± 0.1   |
| Sm. Int. | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 1.5 ± 0.3<br>1.1 ± 0.2   | 0.8 ± 0.04<br>0.6 ± 0.02 | 0.6 ± 0.1<br>0.5 ± 0.1 | 0.2 ± 0.1<br>0.3 ± 0.1   |
| Lg. Int. | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 1.4 ± 0.2<br>0.7 ± 0.1   | 0.9 ± 0.1<br>1.4 ± 0.03  | 0.6 ± 0.1<br>0.4 ± 0.1 | 0.2 ± 0.04<br>0.2 ± 0.04 |
| Muscle   | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 1.3 ± 0.3<br>0.9 ± 0.2   | 0.7 ± 0.2<br>0.6 ± 0.2   | 0.5 ± 0.1<br>0.4 ± 0.1 | 0.2 ± 0.1<br>0.2 ± 0.1   |
| Bone     | <sup>125</sup> I-IMP-R5<br><sup>131</sup> I (CT) | 2.2 ± 0.6<br>1.9 ± 0.7   | 1.3 ± 0.2<br>0.9 ± 0.1   | 1.2 ± 0.5<br>0.6 ± 0.2 | 1.0 ± 0.6<br>0.3 ± 0.2   |

Table-1C: <sup>125</sup>I-IMP-R8-hRS7 versus <sup>131</sup>I-hRS7 (CT method)

| Tissue     | Label   | % ID/g ± SD <sup>1</sup> , n = 5         |  |  |  |
|------------|---|--|--|--|--|
|            |   | 24 h                                     | 72 h                                     | 168 h                                    | 336 h                                    |
| MDA-MB-468 | <sup>125</sup> I-IMP-R8<br><sup>131</sup> I (CT)<br>Tumor wt. | 24.1 ± 5.4<br>8.8 ± 1.6<br>(0.17 ± 0.04) | 26.9 ± 3.9<br>8.8 ± 1.0<br>(0.12 ± 0.05) | 24.7 ± 8.5<br>6.7 ± 2.3<br>(0.10 ± 0.04) | 11.0 ± 6.4<br>2.4 ± 1.3<br>(0.15 ± 0.05) |
| Liver      | <sup>125</sup> I-IMP-R8<br><sup>131</sup> I (CT)              | 4.6 ± 0.7<br>4.1 ± 0.6                   | 3.3 ± 0.4<br>3.3 ± 0.4                   | 1.8 ± 0.2<br>1.8 ± 0.2                   | 0.7 ± 0.2<br>0.8 ± 0.2                   |
| Spleen     | <sup>125</sup> I-IMP-R8<br><sup>131</sup> I (CT)              | 2.6 ± 0.7<br>2.4 ± 0.8                   | 2.3 ± 0.2<br>2.2 ± 0.3                   | 1.9 ± 0.2<br>2.0 ± 0.3                   | 1.0 ± 0.1<br>0.7 ± 0.1                   |
| Kidney     | <sup>125</sup> I-IMP-R8<br><sup>131</sup> I (CT)              | 7.2 ± 0.8<br>2.5 ± 0.3                   | 4.6 ± 0.8<br>3.0 ± 0.7                   | 2.6 ± 1.0<br>1.8 ± 0.5                   | 1.8 ± 0.1<br>0.8 ± 0.3                   |
|            | <sup>125</sup> I-IMP-   | 3.0 ± 0.7                                | 4.7 ± 0.5                                | 2.3 ± 0.6                                | 1.0 ± 0.4                                |

|          |   |                                 |                                |                                |                                |
|----------|---|---------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Lungs    | R8<br>$^{131}\text{I}$ (CT)                           | $2.4 \pm 0.4$                   | $4.4 \pm 0.5$                  | $2.1 \pm 0.5$                  | $1.0 \pm 0.4$                  |
| Blood    | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $10.8 \pm 1.2$<br>$9.2 \pm 1.6$ | $9.6 \pm 0.9$<br>$9.5 \pm 0.8$ | $6.3 \pm 1.4$<br>$6.4 \pm 1.4$ | $2.2 \pm 0.6$<br>$2.6 \pm 0.6$ |
| Stomach  | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $0.9 \pm 0.2$<br>$1.1 \pm 0.2$  | $0.7 \pm 0.2$<br>$0.9 \pm 0.3$ | $0.3 \pm 0.1$<br>$0.4 \pm 0.1$ | $0.2 \pm 0.1$<br>$0.3 \pm 0.1$ |
| Sm. Int. | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $1.0 \pm 0.1$<br>$0.8 \pm 0.1$  | $0.8 \pm 0.2$<br>$0.8 \pm 0.1$ | $0.5 \pm 0.1$<br>$0.5 \pm 0.1$ | $0.2 \pm 0.1$<br>$0.2 \pm 0.1$ |
| Lg. Int. | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $1.0 \pm 0.1$<br>$0.6 \pm 0.1$  | $0.9 \pm 0.1$<br>$0.6 \pm 0.1$ | $0.5 \pm 0.1$<br>$0.4 \pm 0.1$ | $0.3 \pm 0.1$<br>$0.2 \pm 0.1$ |
| Muscle   | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $0.8 \pm 0.1$<br>$0.6 \pm 0.04$ | $0.6 \pm 0.1$<br>$0.6 \pm 0.1$ | $0.4 \pm 0.1$<br>$0.4 \pm 0.1$ | $0.2 \pm 0.1$<br>$0.2 \pm 0.1$ |
| Bone     | $^{125}\text{I}$ -IMP-<br>R8<br>$^{131}\text{I}$ (CT) | $1.4 \pm 0.2$<br>$1.1 \pm 0.2$  | $1.2 \pm 0.3$<br>$0.9 \pm 0.2$ | $1.4 \pm 0.2$<br>$0.7 \pm 0.1$ | $0.8 \pm 0.2$<br>$0.3 \pm 0.1$ |

Dosimetry calculations, based on biodistributions using  $^{125}\text{I}$  in place of  $^{131}\text{I}$ , were performed using the method of Siegel, JA and Stabin, MG (*Journal of Nuclear Medicine* 1994; 35:152-156). Table-2 compares sets of residualizing and conventional radioiodine labels, and Figure-10 describes the data graphically. All of the residualizing agents are seen to perform optimally in terms of dose delivered to tumor and tumor-to-nontumor ratios;  $^{131}\text{I}$ -IMP-R4-hRS7 was chosen for therapy experiments in view of the advantageous radiochemical yields and specific activities obtainable for the same agent.

| <b><u>Table-2: Calculated radiation doses due to variously radioiodinated hRS7 in the MDA-MB-468 tumor model</u></b> |                  |                                     |      |          |      |           |      |
|--|------------------|-------------------------------------|------|----------|------|-----------|------|
| Organ  | Model            | cGy normalized to 1500 cGy to Blood |      |          |      |           |      |
|  |                  | Group I                             |      | Group II |      | Group III |      |
|  |                  | IMP-R4                              | CT   | IMP-R5   | CT   | IMP-R8    | CT   |
| Tumor  | (Trap 0 point 0) | 6995                                | 1613 | 5187     | 1506 | 4000      | 1206 |

|                              |     |       |       |       |           |       |           |
|------------------------------|-----|-------|-------|-------|-----------|-------|-----------|
| Liver                        | Exp | 674   | 456   | 398   | 449       | 497   | 505       |
| Spleen                       | Exp | 535   | 315   | 336   | 313       | 384   | 356       |
| Kidney                       | Exp | 1063  | 402   | 867   | 361       | 761   | 394       |
| Lungs                        | Exp | 450   | 392   | 450   | 422       | 506   | 473       |
| Blood(or<br>g)               | Exp | 1500  | 1500  | 1500  | 1500      | 1500  | 1500      |
| Stomach                      | Exp | 104   | 144   | 84    | 118       | 101   | 128       |
| Sm Int                       | Exp | 148   | 124   | 131   | 119       | 130   | 121       |
| Lg Int                       | Exp | 163   | 108   | 136   | 86        | 140   | 97        |
| Muscle                       | Exp | 112   | 99    | 105   | 100       | 97    | 93        |
| Bone                         | Exp | 486   | 151   | 244   | 149       | 245   | 151       |
| mCi for 1500 cGy to<br>blood |     | 0.231 | 0.285 | 0.213 | 0.23<br>9 | 0.248 | 0.25<br>5 |

*Therapy of MDA-MB-468 human breast carcinoma xenografts in nude mice*

*Maximum-tolerated-dose (MTD):* From dosimetry data (Table-2, group-1), the mCi amounts of  $^{131}\text{I}$ -IMP-R4-hRS7 and  $^{131}\text{I}$ -hRS7, producing a radiation dose of 1500 cGy to blood (estimated MTD) were calculated to be 0.231 mCi and 0.285 mCi, respectively. Experimental determination of MTD was carried out using increasing doses of each agent in Swiss nude mice. For  $^{131}\text{I}$ -IMP-R4-hRS7, groups of animals were administered 200, 225, 250, 275, 300 and 325  $\mu\text{Ci}$ ; 1 out of five animals in the 250  $\mu\text{Ci}$  dose group died by week 4, while 3 out of 4 animals in the 300  $\mu\text{Ci}$  dose group died between weeks 2 and 4. Although the survival of animals in the 275 and 325  $\mu\text{Ci}$  dose groups at five weeks was unexpected, we concluded that the MTD was between 231  $\mu\text{Ci}$  (calculated from dosimetry data) and 250  $\mu\text{Ci}$  of administered dose. For the  $^{131}\text{I}$ -hRS7 ('CT'-based radioiodination), groups of animals were injected with 250, 280, 310, 340, 370 and 400  $\mu\text{Ci}$ ; between weeks 2 and 3, six out of six animals of 340  $\mu\text{Ci}$  dose group, three out of six animals of 370  $\mu\text{Ci}$  dose group, and four out of four animals of 400  $\mu\text{Ci}$  dose group died. Based on these, the MTD was projected to be in the 280-310  $\mu\text{Ci}$  range.

*Therapy Study-1*

For this first therapy experiment, comparing the efficacy of  $^{131}\text{I}$ -IMPR-4-hRS7 with that of  $^{131}\text{I}$ -hRS7 (CT method), each agent used at  $\sim 70\%$  of its maximum-tolerated dose. A single dose of 175  $\mu\text{Ci}$  of the residualizing agent is seen to be significantly more

effective than 200  $\mu$ Ci of conventional radioiodine agent. In this experiment, which also included untreated controls, 10 or 11 animals were used per group, and all the three groups were randomized such that the distribution of starting tumor sizes were very similar. Mean tumor volumes for the three groups before therapy (day -2) were  $0.312 \pm 0.181$ ,  $0.308 \pm 0.203$ , and  $0.303 \pm 0.212$ .

In this experiment, interim data to day 49 are depicted in Figure-11 below. The top panel in Figure-11 shows tumor volumes ( $\text{cm}^3$ ) for individual animals in each group, and the bottom panel indicates mean tumor volumes in two formats. There were three deaths in the untreated group. Tumor growth control is significantly better for the residualizing label group compared to the conventional label and the untreated groups, as determined by the student-t test on the area under the curves (AUC) for mean tumor volumes (MTV) up to day-49. On day 49, significance (p values) for differences in AUCs of MTVs due to therapy with  $^{131}\text{I}$ -IMP-R4-hRS7, with the respective p values for tumor volume differences before therapy (day -2) given in parentheses, are as follows. Versus untreated: 0.05 (0.78); versus  $^{131}\text{I}$ -hRS7 (CT): 0.03 (0.98); for  $^{131}\text{I}$ -hRS7 (CT) versus untreated: 0.14 (0.81). There is continuing divergence in mean tumor volumes between the conventional and the residualizing radioiodine groups on day 49, with the latter group leading to continued decrease. At 8-weeks post-therapy, complete remissions were observed in 5 of 11 mice treated with  $^{131}\text{I}$ -IMP-R4-hRS7, and the MTV was 20% of the starting value. MTV in the untreated and  $^{131}\text{I}$ -hRS7-treated mice at 8 weeks were 280% and 163% of the respective starting values, respectively, with 1 complete remission of 11 mice in the  $^{131}\text{I}$ -hRS7 group.

The treatments were well tolerated. The mean body weights of IMP-R4 group on day -2 was  $21.93 \pm 2.03$  and that on day 49 was  $23.68 \pm 1.81$ ; for 'CT' group, the mean body weights were  $21.77 \pm 2.21$  and  $23.90 \pm 2.64$  on days -2 and 49, respectively. Myelotoxicities of the treated groups, as determined by blood cell counts, are shown in Figure-12. Briefly: With  $^{131}\text{I}$ -IMP-R4-hRS7, nadirs of 34%, 7% and 61% of the control levels for WBC, lymphocyte and neutrophil counts, respectively, were reached one week after the administration of the agent. By week-5, these recovered to 74%, 58% and 92% of the control levels, respectively, and remained at 45%, 36% and 51% of the control

levels on day-49; and for  $^{131}\text{I}$ -hRS7 (CT): nadirs of 41%, 13% and 67% of the control levels for WBC, lymphocyte and neutrophil counts, respectively, were reached one week after the administration of the agent. By week-5, these recovered to 85%, 67% and 103% of the control levels, respectively, and remained at 42%, 32% and 49% of the control levels on day-49.

#### *Therapy Study-2*

##### *Specificity of RAIT using $^{131}\text{I}$ -IMP-R4-hRS7 in the MDA-MB-468 tumor model*

The efficacy of  $^{131}\text{I}$ -IMP-R4-hRS7 was compared with that of non-specific control humanized antibody, hLL2 (anti-CD-22 MAbs), labeled with  $^{131}\text{I}$ -IMP-R4. In this experiment, 175  $\mu\text{Ci}$  of each agent was administered. This represents  $\sim 70\%$  of the maximum-tolerated dose of  $^{131}\text{I}$ -IMP-R4-hRS7. In this experiment, which included untreated controls, 7-to-8 animals were used per group, and the groups were randomized with regard to the starting tumor volume distributions as in therapy experiment-1. Figure 13, showing the *relative* mean tumor volumes (MTV) for the three groups (MTV before therapy: 100), is indicative of the growth control specificity.

#### **Example 5. Treatment of a breast cancer patient with Y-90 humanized RS7 mAb and with naked humanized RS7 mAb:**

A 56-year-old woman with a history of recurrent adenocarcinoma of the breast presents with cervical lymph node and left lung metastases. She relapses twice after chemotherapy and hormonal therapies. She is then given two therapeutic injections, two weeks apart, of Y-90-conjugated humanized RS7 mAb i.v., at a dose each of 20 mCi Y-90 in a protein dose of antibody of 100 mg. Four weeks after therapy, her white blood cell and platelet counts have decreased by approximately 50%, but recuperate by 9 weeks post-therapy. At the restaging 12 weeks post-therapy, a ca. 30% decrease in pulmonary and nodal metastases has been measured by computed tomography. Thereafter, she receives 4 weekly infusions, over 3 hours each, of naked humanized RS7, which is tolerated well, except for some transient rigors and chills, and without any adverse effects on her blood counts or blood chemistries. The naked antibody dose for each infusion was  $400 \text{ mg/m}^2$ . Approximately 8 weeks later, restaging by computed tomography indicates



an additional decrease in measurable lesions by about 20 percent. At the followup examination 3 months later, her disease appears to be stable (i.e., no evidence of additional, or progressive growth).

**WHAT IS CLAIMED:**

1. An antibody or fragment thereof that binds to an EGP-1 glycoprotein.
2. The antibody or fragment thereof of claim 1, wherein said antibody or fragment thereof is an RS7 antibody or fragment thereof.
3. The antibody or fragment thereof of claim 2, wherein said antibody or fragment thereof is humanized.
4. The antibody or fragment thereof of claim 2, wherein said antibody or fragment thereof is fully human.
5. The humanized antibody or fragment thereof of claim 3, wherein the complementarity determining regions (CDRs) of the light chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT.
6. The humanized antibody or fragment thereof of claim 3, wherein the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV.
7. The humanized antibody or fragment thereof of claim 3, comprising the CDRs of a murine RS7 MAb and the framework region (FR) of the light and heavy chain variable regions of a human antibody, wherein the CDRs of the light chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT; and the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of

WINTYTGEPITYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV.

8. The humanized antibody or fragment thereof of claim 7, further comprising the FRs of the light and heavy chain constant regions of a human antibody.

9. The humanized antibody or fragment thereof of claim 3, wherein the FRs of the light or heavy chain variable regions of said humanized antibody comprise at least one amino acid substituted by an amino acid residue found at a corresponding location in the murine RS7 MAb.

10. The humanized antibody or fragment thereof of claim 9, wherein at least one of the substituted amino acid residues is at the location selected from the group consisting of amino acid residue 38, 46, 68 and 91 of the murine heavy chain variable region of Fig. 3B.

11. The humanized antibody or fragment thereof of claim 9, wherein at least one of the substituted amino acid residues is at the location selected from the group consisting of amino acid residue 20, 85 and 100 of the murine light chain variable region Fig. 3A.

12. The antibody or fragment thereof of claim 2, wherein said antibody or fragment thereof is chimeric.

13. The antibody or fragment thereof of claim 12, wherein said antibody or fragment thereof comprises RS7 V<sub>K</sub> nucleotide sequence of figure 2A and the RS7 V<sub>H</sub> nucleotide sequence of figure 2B.

14. The antibody or fragment thereof of claim 3, wherein said antibody or fragment thereof comprises a hRS7 V<sub>K</sub> nucleotide sequence of figure 4A and a hRS7 V<sub>H</sub> nucleotide sequence of figure 4B.

15. A cancer cell targeting diagnostic or therapeutic conjugate comprising an antibody component comprising an anti-EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of claims 1-14 that binds to said cell, wherein said antibody component is bound to at least one diagnostic or at least one therapeutic agent.

16. The diagnostic conjugate according to claim 15, wherein said diagnostic agent comprises at least one photoactive diagnostic agent.

17. The diagnostic conjugate of claim 15, wherein said diagnostic agent is a radioactive label with an energy between 25 and 4,000 keV.

18. The diagnostic conjugate of claim 17, wherein said radioactive label is a gamma-, beta- or a positron-emitting isotope.

19. The diagnostic conjugate of claim 18, wherein said radioactive label is selected from the group consisting of  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{86}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{111}\text{In}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{94\text{m}}\text{Tc}$ ,  $^{18}\text{F}$ ,  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{O}$ ,  $^{177}\text{Lu}$  and  $^{76}\text{Br}$ .

20. The diagnostic conjugate of claim 15, wherein said diagnostic agent is a contrast agent.

21. The diagnostic conjugate of claim 20, wherein said contrast agent is a paramagnetic ion.

22. The diagnostic conjugate of claim 20, wherein said contrast agent is an ultrasound- enhancing agent.

23. The diagnostic conjugate of claim 22, wherein said ultrasound enhancing agent is a liposome that comprises a humanized RS7 IgG or fragment thereof.

24. The diagnostic conjugate of claim 23, wherein said liposome is gas filled.

25. A diagnostic conjugate of claim 21, wherein said paramagnetic ion is a metal comprising manganese, iron or gadolinium.

26. A therapeutic conjugate of claim 15, wherein said antibody component is an antibody fusion protein or fragment thereof, wherein each of said MAbs or fragments thereof are bound to at least one therapeutic agent.

27. A therapeutic conjugate of claim 15 or 26, wherein said therapeutic agent is selected from the group consisting of a radioactive label, an immunomodulator, a hormone, an enzyme, a photoactive therapeutic agent, a cytotoxic agent and a combination thereof.

28. A therapeutic conjugate of claim 27, wherein said cytotoxic agent is a drug or a toxin.

29. A therapeutic conjugate of claim 28, wherein said drug possesses the pharmaceutical property selected from the group consisting of antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkylid, and antibiotic agents and combinations thereof.

30. A therapeutic conjugate of claim 28, wherein said drug is selected from the group consisting of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, anthracyclines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antibiotics, enzymes, epipodophyllotoxins, platinum coordination complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, antagonists, endostatin, taxols, camptothecins, doxorubicins and their analogs, and a combination thereof.

31. A therapeutic conjugate of claim 28, wherein said toxin is selected from the group consisting of ricin, abrin, alpha toxin, saporin, ribonuclease (RNase), DNase I, *Staphylococcal* enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, *Pseudomonas* exotoxin, and *Pseudomonas* endotoxin.

32. A therapeutic conjugate of claim 27, wherein said immunomodulator is selected from the group consisting of a cytokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), a stem cell growth factor, erythropoietin, thrombopoietin and a combination thereof.

33. A therapeutic conjugate of claim 32, wherein said lymphotoxin is tumor necrosis factor (TNF), said hematopoietic factor is an interleukin (IL), said colony stimulating factor is granulocyte-colony stimulating factor (G-CSF) or granulocyte

macrophage-colony stimulating factor (GM-CSF)), said interferon is interferons- $\alpha$ , - $\beta$  or - $\gamma$ , and said stem cell growth factor is designated "S1 factor".

34. The diagnostic conjugate of claim 15, wherein said radionuclide has an energy between 60 and 4000 keV.

35. The therapeutic conjugate of claim 32, wherein said immunomodulator comprises IL-1, IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, IL-21, interferon- $\gamma$ , TNF- $\alpha$  or a combination thereof.

36. A therapeutic conjugate of claim 27, wherein said radioactive label has an energy between 60 and 700 keV.

37. A therapeutic conjugate of claim 27, wherein said radioactive label is selected from the group consisting of  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{47}\text{Sc}$ ,  $^{64}\text{Cu}$ ,  $^{67}\text{Cu}$ ,  $^{67}\text{Ga}$ ,  $^{86}\text{Y}$ ,  $^{90}\text{Y}$ ,  $^{111}\text{Ag}$ ,  $^{111}\text{In}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{142}\text{Pr}$ ,  $^{153}\text{Sm}$ ,  $^{161}\text{Tb}$ ,  $^{166}\text{Dy}$ ,  $^{166}\text{Ho}$ ,  $^{177}\text{Lu}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{189}\text{Re}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{223}\text{Ra}$  and  $^{225}\text{Ac}$ , and combinations thereof.

38. A therapeutic conjugate of claim 27, wherein said photoactive therapeutic agent is a chromogen or dye.

39. A multivalent, multispecific antibody comprising one or more antigen-binding sites having affinity toward a EGP-1 target antigen and one or more hapten binding sites having an affinity toward a hapten molecule.

40. The antibody of claim 39, wherein said antibody is humanized.

41. The antibody of claim 39, wherein said antibody is a human antibody.

42. The antibody of claim 39, wherein said antibody is chimerized.

43. The antibody of claim 39, further comprising a diagnostic or therapeutic agent.

44. An antibody fusion protein or fragment thereof comprising at least two anti-EGP-1 MAbs or fragments thereof, wherein said MAbs or fragments thereof are selected from said MAb or fragment thereof of any one of claims 1-43.

45. An antibody fusion protein or fragment thereof comprising at least one first anti-EGP-1 MAb or fragment thereof of any one of claims 1-43 and at least one second MAb or fragment thereof, other than the MAb or fragment thereof of any one of claims 1-43.

46. The antibody fusion protein or fragment thereof of claim 45, wherein said second MAb is a carcinoma-associated antibody.

47. The antibody fusion protein or fragment thereof of claim 46, wherein said carcinoma-associated antibody binds to an antigen on a cancer selected from the group consisting of head-and-neck, lung, breast, ovarian, stomach, prostate, colon, and/or urinary bladder cancer.

48. The antibody fusion protein or fragment thereof of claim 46 wherein said carcinoma-associated antibody is an antibody or fragment reactive with the antigen selected from the group consisting of CEA, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, AFP, HCG, HCG-beta, ferritin, PAP, PLAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, VEGF, P1GF, insulin-like growth factor, oncogene products, and a combination thereof.

49. A DNA sequence comprising a nucleic acid encoding a MAb or fragment thereof selected from the group consisting

- (a) an anti-EGP-1 MAb or fragment thereof of any one of claims 1-43;
- (b) an antibody fusion protein or fragment thereof comprising at least two of said MAbs or fragments thereof;
- (c) an antibody fusion protein or fragment thereof comprising at least one first anti-EGP-1 MAb or fragment thereof comprising said MAb or fragment thereof of any one of claims 1-43 and at least one second MAb or fragment thereof, other than the MAb or fragment thereof of any one of claims 1-43; and

(d) an antibody fusion protein or fragment thereof comprising at least one first MAb or fragment thereof comprising said MAb or fragment thereof of any one of claims 1-43 and at least one second MAb or fragment thereof, other than the MAb or fragment thereof of any one of claims 1-39 wherein said second MAb is an antibody or fragment reactive with the antigen selected from the group consisting of CEA, CSAP, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, AFP, HCG, HCG-beta, ferritin, PAP, PLAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, VEGF, P1GF, insulin-like growth factor, oncogene products, and a combination thereof.

50. An expression vector comprising the DNA sequence of claim 49.

51. A host cell comprising the DNA sequence of claim 49.

52. A method of delivering a diagnostic or therapeutic agent, or a combination thereof, to a target comprising (i) providing a composition that comprises an anti-EGP-1 antibody bound to at least one diagnostic or at least one therapeutic agent and (ii) administering to a subject in need thereof said composition.

53. The method of claim 52, wherein said diagnostic or therapeutic agent is selected from the group consisting of an isotope, drug, toxin, immunomodulator, enzyme, hormone, growth factor, radionuclide, metal, contrast agent and detecting agent.

54. The method of claim 53, wherein said diagnostic or therapeutic agent is an immunomodulator selected from the group consisting of a cytokine, stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor, interferon, erythropoietin, thrombopoietin, and a combination thereof

55. The method of claim 54, wherein said diagnostic or therapeutic agent is a cytokine.

56. The method of claim 53, wherein said diagnostic or therapeutic agent is an isotope.



57. The method of claim 56, wherein said isotope has a range of energy between 25 to 4,000 keV.

58. The method of claim 56, wherein said isotopes are selected from the group comprising  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{86}\text{Y}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{189}\text{Re}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{67}\text{Cu}$ ,  $^{111}\text{In}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{94\text{m}}\text{Tc}$ ,  $^{94}\text{Tc}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{18}\text{F}$ ,  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{O}$ ,  $^{52}\text{Fe}$ ,  $^{89}\text{Zr}$ ,  $^{154-158}\text{Gd}$ ,  $^{177}\text{Lu}$ ,  $^{76}\text{Br}$ ,  $^{225}\text{Ac}$ ,  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{47}\text{Sc}$ ,  $^{111}\text{Ag}$ ,  $^{142}\text{Pr}$ ,  $^{153}\text{Sm}$ ,  $^{161}\text{Tb}$ ,  $^{166}\text{Dy}$ ,  $^{166}\text{Ho}$ ,  $^{212}\text{Pb}$ , and  $^{223}\text{Ra}$ .

59. The method of claim 53, wherein said drugs are selected from the group consisting of a cytotoxic drug, photodynamic drug, fluorochrome and immune modulators.

60. The method of claim 53, wherein said diagnostic or therapeutic agent is a metal.

61. The diagnostic agent of claim 60, which is a paramagnetic ion used for MRI.

62. The method of claim 61, wherein said contrast agent is gadolinium, iron or manganese.

63. The method of claim 53, wherein said detection agents are selected from the group consisting of a fluorescent compound, chemiluminescent compound, bioluminescent compound.

64. The method of claim 63, wherein said detection agent is a fluorescent compound.

65. The method of claim 64, wherein said fluorescent compound is selected from the group consisting of fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

66. The method of claim 63, wherein said detection agent is a chemiluminescent compound.

67. The method of claim 63, wherein said chemiluminescent compound is selected from the group consisting of luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.

68. The method of claim 63, wherein said detection agent is a bioluminescent compound.

69. The method of claim 68, wherein said bioluminescent compound is selected from the group consisting of luciferin, luciferase and aequorin.

70. The method of claim 53, wherein said contrast agent is an ultrasound contrast agent.

71. The method of claim 70, wherein said ultrasound enhancing agent is a liposome that comprises a humanized RS7 IgG or fragment thereof.

72. The diagnostic conjugate of claim 64, wherein said liposome is gas filled.

73. The method of any of claims 52-72, wherein said anti-EGP-1 antibody is a RS7 antibody.

74. A method of delivering a diagnostic agent, a therapeutic agent, or a combination thereof to a target, comprising:

- (i) administering to a subject the antibody of claim 39;
- (ii) waiting a sufficient amount of time for an amount of the non-binding antibody to clear a subject's blood stream, and
- (iii) administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody.

75. The method of claim 74, wherein said hapten binds to more than one binding site of said antibody.

76. The method of claim 74, wherein said diagnostic agent or said therapeutic agent is selected from the group comprising isotopes, drugs, toxins, cytokines, enzymes, hormones, growth factors, conjugates, radionuclides, and metals.

77. A method for diagnosing or treating cancer, comprising:

- (i). administering to a subject in need thereof the antibody of claim 39;
- (ii). waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and
- (iii). administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody.

78. The method of claim 77, wherein said cancer is selected from the group consisting of lung, ovarian, prostate, colon, stomach, bladder and breast cancer.

79. A method of treating a malignancy in a subject comprising administering to said subject a therapeutically effective amount of an antibody fusion protein or fragment thereof comprising at least two MAbs or fragments thereof, wherein said MAbs are selected from said MAbs of any one of claims 1-44 or comprising at least one MAb or fragment thereof of any one of claims 1-44 formulated in a pharmaceutically suitable excipient.

80. A method of treating a malignancy in a subject comprising administering to said subject a therapeutically effective amount of a therapeutic conjugate comprising a EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of claims 1-48, wherein said EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof is bound to at least one therapeutic agent, formulated in a pharmaceutically suitable excipient.

81. The method of claim 80, wherein said therapeutic agent is selected from the group consisting of a nitrogen mustard, ethylenimine derivative, alkyl sulfonate, nitrosurea, traizene, folic acid analog, anthracycline, taxane, COX-2 inhibitor, tyrosine kinase inhibitor, pyrimidine analog, purine analog, antibiotic, enzyme, epipodophyllotoxin, platinum

coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocortical suppressant, antagonist, endostatin taxol, camptothecins, doxorubicin, doxorubicin analog, and a combination thereof.

82. The method of claim 80, wherein said therapeutic agent is a drug that possesses the pharmaceutical property selected from the group consisting of an antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkylid antibiotic, and combinations thereof.

83. The method of claim 80, further comprising a second Mab or fragment thereof or antibody fusion protein or fragment thereof not in any one of claims 1-48.

84. The method of claim 83, wherein said second Mab or fragment thereof or antibody fusion protein or fragment thereof is a naked Mab or fragment thereof.

85. The method of claim 83, wherein said second MAb or fragment thereof or antibody fusion protein or fragment thereof is reactive with the antigen selected from the group consisting of CEA, AFP, HCG, CSAP, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, VEGF, P1GF, insulin-like growth factor, tenascin, oncogene products, cytokeratin, and A33.

86. The method of claim 85, wherein said second MAb or fragment thereof or antibody fusion protein or fragment thereof is conjugated to a therapeutic or diagnostic agent.

87. The method of claim 80, further comprising a second Mab or fragment thereof of any one of claims 1-38.

88. The method of claim 80, wherein said anti-EGP-1 antibody or fragment thereof or antibody fusion protein or fragment thereof is administered parenterally.

89. The method of claim 88, wherein said anti-EGP-1 antibody or fragment thereof or antibody fusion protein or fragment thereof is administered in a dosage of 10 to 2000 milligrams protein per dose.

90. The method of claim 89, wherein said dosage is repeatedly administered.

91. The method of claim 80, wherein said anti-EGP-1 antibody or fragment thereof is selected from the group consisting of a subhuman primate anti-EGP-1 antibody, murine monoclonal anti-EGP-1 antibody, chimeric anti-EGP-1 antibody, human anti-EGP-1 antibody, and humanized anti-EGP-1 antibody.

92. The method of claim 91, wherein said chimeric, human and humanized anti-EGP-1 antibody constant and hinge regions comprise constant and hinge regions of a human IgG1.

93. The method of claim 83, wherein said anti-EGP-1 antibody or fragment thereof or antibody fusion protein or fragment thereof is administered before, in conjunction with, or after a second antibody or fragment thereof is administered to said subject.

94. The method of claim 80, wherein a first binding site of the anti-EGP-1 antibody or fragment thereof is present in a multivalent, multispecific fusion protein or chemical conjugate and a second binding site is reactive with a tumor marker substance other than EGP-1.

95. The method of claim 80, wherein said anti-EGP-1 antibody or fragment thereof or antibody fusion protein or fragment thereof is administered before, concurrently, or after at least one therapeutic agent.

96. The method of claim 93, wherein said second antibody or fragment thereof is conjugated to at least one therapeutic or diagnostic agent.

97. The method of any of claims 80-96, wherein said anti-EGP-1 antibody is a RS7 antibody.

98. A method of diagnosing a malignancy in a subject comprising administering to said subject a therapeutically effective amount of a therapeutic conjugate comprising a anti-EGP-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of claims 1-48, wherein said anti-EGP-1 MAb or fragment thereof or antibody fusion

protein or fragment thereof is bound to at least one diagnostic agent, formulated in a pharmaceutically suitable excipient.

99. A method of treating a cancer cell in a subject comprising (i) administering to said subject a therapeutically effective amount of a composition comprising a naked anti-EGP-1 MAb or fragment thereof or a naked antibody fusion protein or fragment thereof of any one of claims 1-14 and 44-48, (ii) formulating said naked EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof in a pharmaceutically suitable excipient.

100. The method of claim 99, wherein said composition further comprises a second naked antibody or fragment thereof not in any one of claims 1-14 and 44-48.

101. The method of claim 99, wherein said composition further comprises a second antibody or fragment thereof of any one of claims 1-48.

102. The method of claim 99, wherein said composition further comprises a second antibody or fragment thereof not in any one of claims 1-38.

103. The method of claim 100, wherein said second antibody or fragment thereof is reactive with the antigen selected from the group consisting of CEA, AFP, HCG, CSAP, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, VEGF, P1GF, insulin-like growth factor, tenascin, oncogene products, cytokeratin, and A33.

104. The method of claim 102, wherein said second antibody or fragment thereof is reactive with the antigen selected from the group consisting of CEA, AFP, HCG, CSAP, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, VEGF, P1GF, insulin-like growth factor, tenascin, oncogene products, cytokeratin, and A33.

105. The method of claim 99, wherein said naked anti-EGP-1 antibody or fragment thereof or naked antibody fusion protein or fragment thereof is administered parenterally.

106. The method of claim 105, wherein said naked anti-EGP-1 antibody or fragment thereof or naked antibody fusion protein or fragment thereof is administered in a dosage of 10 to 2000 milligrams protein per dose.

107. The method of claim 106, wherein said dosage is repeatedly administered.

108. The method of claim 99, wherein said naked anti-EGP-1 antibody or fragment thereof is selected from the group consisting of subhuman primate anti-EGP-1 antibody, murine monoclonal anti-EGP-1 antibody, chimeric anti-EGP-1 antibody, human anti-EGP-1 antibody, and humanized anti-EGP-1 antibody.

109. The method of claim 108, wherein said chimeric, human and humanized naked anti-EGP-1 antibody constant and hinge regions comprise constant and hinge regions of a human IgG1.

110. The method of claim 102, wherein said naked anti-EGP-1 antibody or fragment thereof or naked antibody fusion protein or fragment thereof is administered before, in conjunction with, or after a second naked antibody or fragment thereof reactive with a second tumor marker expressed by said malignancy is administered to said subject.

111. The method of claim 99, wherein said naked anti-EGP-1 antibody is administered before, concurrently or after a therapeutic agent.

112. The method of any of claims 99-111, wherein said naked anti-EGP-1 antibody is a naked RS7 antibody.

113. A method of diagnosing a malignancy in a subject comprising (i) performing an *in vitro* diagnosis assay on a specimen from said subject with a composition comprising a naked anti-EGP-1 MAb or fragment thereof or a naked antibody fusion protein or fragment thereof of any one of claims 1-14 and 44-48.

114. The method of claim 113, wherein said malignancy is a carcinoma.

115. The method of claim 114, wherein said cancer is selected from the group of head-and-neck, lung, prostate, ovarian, breast, colon, stomach, and bladder cancer.

116. The method of claim 113, wherein said *in vitro* diagnosis assay is selected from the group consisting of immunoassays, RT-PCR and immunohistochemistry.

117. The method of claim 116, wherein said *in vitro* diagnosis assay is RT-PCR or immunoassays.

118. The method of claim 117, wherein said specimen is body fluid or a tissue.

119. The method of claim 116, wherein said diagnosis assay is immunohistochemistry.

120. The method of claim 119, wherein said specimen is a cell or a tissue.

121. Use of a naked anti-EGP-1 MAb or fragment thereof or a naked antibody fusion protein or fragment thereof of any one of claims 1-14 and 44-48 for the treatment of cancer.

122. Use of therapeutic conjugate comprising a EGF-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of claims 1-48, wherein said EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof is bound to at least one therapeutic agent for the treatment of a malignancy.

123. Use of diagnostic conjugate comprising a EGF-1 MAb or fragment thereof or an antibody fusion protein or fragment thereof of any one of claims 1-48, wherein said EGP-1 MAb or fragment thereof or antibody fusion protein or fragment thereof is bound to at least one therapeutic agent for the diagnosis of a malignancy.

124. Use of a diagnostic agent, a therapeutic agent or a combination thereof comprising at least one antibody of any one of claims 39-48 for the targeting an EGP-1 target antigen on a cell.






Figure 1.

RS7Vk

GACATTGAGCTGACCCAGTCTCACAAATTTCATGTCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGT 90  
 1 10 20 30  
 D I Q L T Q S H K F M S T S V G D R V S I T C K A S Q D V S L1  
 ATTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTACTCGGCATCCTACCGGTACACTGGAGTCCCTGAT 180  
 40 50 60  
 I A V A W Y Q Q K P G Q S P K L L I Y S A S Y R Y T G V P D L2  
 CGCTTCACTGGCAGTGGATCTGGGACGGATTTCACITTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAA 270  
 70 80 90  
 R F T G S G S G T D F T F T I S S V Q A E D L A V Y C Q Q  
 CATTATATTACTCCGCTCACGTTCCGTGCTGGGACCAAGCTGGAGCTGAACGG 324  
 100 108  
 H Y I T P L T F G A G T K L E L K R L3

Figure 2A.

RS7VH

|   |     |
|---|-----|
| GTGAAGCTGCAGGAGTCAGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGATATACCTTCACAAAC    | 90  |
| 2   | 30  |
| V K L Q E S G P E L K K P G E T V K I S C K A S G Y T F T N                                   | 30  |
| TATGGAATGAACCTGGGTGAAGCAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAAACACCTACACTGGAGAGCCCAACATATACT | 180 |
| 40  | 60  |
| Y G M N W V K Q A P G K G L K W M G W I N T Y T G E P T Y T                                   | 60  |
| H1  | H2  |
| GATGACTTCAAGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCACCACCTGCCTATTTCAGATCAACAACCTCAAAAAGTGAGGACATG    | 270 |
| 70  | 80  |
| D D F K G R F A F S L E T S A T T A Y L Q I N N L K S E D M                                   | 80  |
| GCTACATATTTCTGTGCAAGAGGGGGTTCGGTAGTAGCTACTGGTACTTCGATGTCCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA    | 360 |
| 90  | 110 |
| A T Y F C A R G G F G S S Y W Y F D V W G Q G T T V T V S S                                   | 113 |
|   | H3  |

Figure 2B.

|           |  |    |    |    |    |
|-----------|--|----|----|----|----|
|           | 1  | 10 | 20 | 30 | 40 |
| SA-1A' c1 | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKP |    |    |    |    |
| RS7       | DIQL●●HKFM●T●●●●S●●●K●●DV●IAVA●●●●●      |    |    |    |    |
| hRS7      | DIQL●●●●●●●●●●S●●●K●●DVSIAVA●●●●●        |    |    |    |    |

|           |   |    |    |    |
|-----------|---|----|----|----|
|           | 50                                      | 60 | 70 | 80 |
| SA-1A' CL | GKAPKLLIYAASSLQSGVPSRFSGSGTGDTFTLTISLQP |    |    |    |
| RS7       | ●QS●●●●●S●YRYT●●D●T●●●●●F●●●V●A         |    |    |    |
| hRS7      | ●●●●●●●S●YRYT●●D●●●●●●●●●●●●●●●         |    |    |    |

|           |                              |     |     |
|-----------|------------------------------|-----|-----|
|           | 90                           | 100 | 108 |
| SA-1A' CL | EDFATYYCQQQSYSTPLTFGGGKVEI-- |     |     |
| RS7       | ●L●V●●●●H●I●●●●A●●L●LKR      |     |     |
| hRS7      | ●●●V●●●H●I●●●●A●●●●IKR       |     |     |

Figure 3A.

|        |       |                             |        |       |    |
|--------|-------|-----------------------------|--------|-------|----|
| RF-TS3 | 1     | 10                          | 20     | 30    | 40 |
|        | -     | VQLVQSGSELKKPGASVKVCKASGYTF | TSYAMN | WVRQA |    |
| RS7    | -     | VKLQE                       | P      | ET    | I  |
|        |       |                             |        |       |    |
| hRS7   | QVQLQ |                             |        |       |    |

|        |            |              |          |           |
|--------|------------|--------------|----------|-----------|
| RF-TS3 | 50         | 52 A         | 60       | 70        |
|        | PGQGLEWMGW | INTNTGNPTYAQ | FTGRFVFS | LDTSVSTAY |
| RS7    |            | K            | K        |           |
|        |            |              |          |           |
| hRS7   |            |              |          |           |

|        |                     |          |     |             |     |
|--------|---------------------|----------|-----|-------------|-----|
| RF-TS3 | 80                  | 82 A B C | 90  | 100 A B C D | 102 |
|        | LQISSLKADDTAVYYCARE | DSNGYKIF | -DY |             |     |
| RS7    |                     | NN       | SE  | M           | T   |
|        |                     |          |     |             |     |
| hRS7   |                     |          |     |             |     |

|      |       |     |      |
|------|-------|-----|------|
| NEWM | 103   | 110 | 113  |
|      | WGQGS | LV  | TVSS |
| RS7  |       |     |      |
| hRS7 |       |     |      |

Figure 3B.

hRS7Vk

|  |     |
|--|-----|
| GACATCCAGCTGACCCAGTCTCCATCCTCCCTGTCTGTGCATCTGTAGGAGACAGAGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGT | 90  |
| D I Q L T Q S P S S L S A S V G D R V S I T C <u>K A S Q D V S</u>                           | 30  |
|  | L1  |
| ATTGCTGTAGCCTGGTATCAGCAGAAACCAGGAAAGCCCTAAGCTCCTGATCTACTCGGCATCCTACCGGTACACTGGAGTCCCTGAT     | 180 |
| <u>I A V A W Y Q Q K P G K A P K L L I Y S A S Y R Y T G V P D</u>                           | 60  |
|  | L2  |
| AGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCCTGAAGATTTTGCAGTTTATTACTGTGAGCAA  | 270 |
| R F S G S G S G T D F T L T I S S L Q P E D F A V Y Y C <u>Q Q</u>                           | 90  |
|  |     |
| CATTATATTACTCCGCTCACGTTCCGGTCTGGGACCAAGGTGGAGATCAAAACGT                                      | 324 |
| <u>H Y I T P L T F G A G T K V E I K R</u>   | 108 |
|  | L3  |

Figure 4A.

hRS7VH

|          |           |         |         |        |         |          |         |        |        |        |        |       |       |        |       |       |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
|----------|-----------|---------|---------|--------|---------|----------|---------|--------|--------|--------|--------|-------|-------|--------|-------|-------|-------|------|-----|---|---|---|---|---|---|---|---|---|---|-----|
| CAGGTCCA | ACTGCAGCA | ATCTGGG | TCTGAGT | TGAAGA | CCCTGGG | CCCTCAGT | GAAGG   | TTTCCT | GCAAGG | CTTCTG | GATAC  | ACCTT | CACA  | 90     |       |       |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
| Q        | V         | Q       | L       | Q      | Q       | S        | G       | S      | E      | L      | K      | K     | P     | G      | A     | S     | V     | K    | V   | S | C | K | A | S | G | Y | T | F | T | 30  |
|          |           |         |         |        |         |          |         |        |        |        |        |       |       |        | H2    |       |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
| AACTATG  | GAATGAA   | CTGGG   | TGAAG   | CAAGC  | CCCTGG  | ACAAAGG  | GGCTTAA | ATGGAT | GGGCTG | GATAAA | CACCTA | CAC   | TGGAG | AGCCAA | CATAT | 180   |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
| N        | Y         | G       | M       | N      | W       | V        | K       | Q      | A      | P      | G      | Q     | G     | L      | K     | W     | M     | G    | W   | I | N | T | Y | T | G | E | P | T | Y | 59  |
| H1       |           |         |         |        |         |          |         |        |        |        |        |       |       |        | H2    |       |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
| ACTGATG  | ACTTCA    | AGGACG  | GTTTGC  | CTTCTC | CTTGG   | ACACCT   | CTGTG   | CAGC   | ACGG   | CATAT  | CTCC   | AGAT  | CAGC  | AGCCT  | AAAGG | CTGAC | GAC   | 270  |     |   |   |   |   |   |   |   |   |   |   |     |
| T        | D         | D       | F       | K      | G       | R        | F       | A      | F      | S      | L      | D     | T     | S      | V     | S     | T     | A    | Y   | L | Q | I | S | S | L | K | A | D | D | 86  |
| ACTGCCG  | TGTA      | TTTCT   | GTGCA   | AGAGG  | GGGTT   | CGGTAG   | TAGT    | ACTTGG | TACTT  | CGATG  | TCTG   | GGG   | CCCA  | AGGGT  | CCC   | TGGT  | CACCC | GTCT | 360 |   |   |   |   |   |   |   |   |   |   |     |
| T        | A         | V       | Y       | F      | C       | A        | R       | G      | G      | F      | G      | S     | S     | Y      | W     | Y     | F     | D    | V   | W | G | Q | G | S | L | V | T | V | S | 112 |
|          |           |         |         |        |         |          |         |        |        |        |        |       |       |        | H3    |       |       |      |     |   |   |   |   |   |   |   |   |   |   |     |
| TCA      |           |         |         |        |         |          |         |        |        |        |        |       |       |        |       |       |       |      |     |   |   |   |   |   |   |   |   |   |   | 363 |
| S        |           |         |         |        |         |          |         |        |        |        |        |       |       |        |       |       |       |      |     |   |   |   |   |   |   |   |   |   |   | 113 |

Figure 4B.

ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCGACATCCAGTGCACCCAGTCTCCATCCTCTGCTGCACTCTGTAGGAGACAGAGTCAGCATC 120  
M G W S C I I L F L V A T A T G V H S D I Q L T Q S P S S L S A S V G D R V S I 40  
 ACCTGCAAGGCCAGTCAGGATGTGAGTATTGCTGTAGCCTGGTATCAGCAGAAACCCAGGGAAGCCCTAAGCTCCTGATCTACTCGGCATCCTACCGGTACACTGGAGTCCCTGATAGG 240  
 T C K A S Q D V S I A V A W Y Q Q K P G K A P K L L I Y S A S Y R Y T G V P D R 80  
 TTCAGTGGCAGTGGACAGATTTCACCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAGTTTATTACTGTGAGCAACATTATATTACTCCGCTCACGTTCCGTTGCTGGG 360  
 F S G S G S G T D F T L T I S S L Q P E D F A V Y Y C Q Q H Y I T P L T F G A G 120  
 ACCAAGGTGGAGATCAAACGTACTGTGGCTGCACCATCTGTCTTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCACTGCTGTGCTGCTGCTGAATACTTCTATCCC 480  
 T K V E I K R T V A A P S V F I F P P S D E Q L K S G T A S V V C L L N N F Y P 160  
 AGAGAGGCCAAAGTACAGTGGAAAGTGGATAACGCCCTCCCAATCGGGTAACCTCCAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCCTGACGCTG 600  
 R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y S L S S T L T L 200  
 AGCAAAGCAGACTACGAGAAACACAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCAAAAGAGCTTCAACAGGGGAGAGTGTAG 702  
 S K A D Y E K K V Y A C E V T H Q G L S S P V T K S F N R G E C \* 233

Figure 5A.



**Figure 5B.**




Figure 6.

ATGGGATGGAGCTGTATCATCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCGACATCCAGCTGACCCAGTCTCCATCCTCCTGTCTGCATCTCTGAGGAGACAGAGTCAGCATC 120  
M G W S C I I L F L V A T A T G V H S D I Q L T Q S P S L S A S V G D R V S I 40  
 ACCTGCAAGGCCAGTCAGGATGTGAGTATTGCTGTAGCCTGGTATCAGCAGAAACCCAGGAAGCCCCCTAAGCTCCTGATCTACTCGGCATCCTACCGGTACACTGGAGTCCCTGATAGG 240  
 T C K A S Q D V S I A V A W Y Q Q K P G K A P K L L I Y S A S Y R Y T G V P D R 80  
 TTCAGTGGCAGTGGATCTGGGACAGATTTCACCTCACCATCAGCAGTCTGCAACCTGGAAGATTTGCAAGTTTACTGTCAAGCAACATATATTAATCTCCGCTCACGTTCCGGTGGTGGG 360  
 F S G S G S G T D F T L T I S S L Q P E D F A V Y Y C Q Q H Y I T P L T F G A G 120  
 ACCAAGGTGGAGATCAAAACGTACTGTGGCTGGCACCATCTGTCTTTCATCTTCCCGCCCATCTGATGAGCAGTTGAAATCTGGAATCTGGAATCTGTGTGCTGCTGAAATAACTTCTATCCC 480  
 T K V E I K R T V A A P S V F I F P P S D E Q L K S G T A S V V C L L N N F Y P 160  
 AGAGAGGCCCAAGTACAGTGAAGGTGATACGCCCTTCCAATCGGGTAACCTCCAGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCCTGACCGTGG 600  
 R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K D S T Y S L S S T L T L 200  
 AGCAAGCAGACTACGAGAAACACAAAGTCTACGCCCTGCCAAGTCAACCCATCAGGGCCTGAGTCCGCCCTCACAAAGAGCTTCAACAGGGGAGAGTGTAG 702  
 S K A D Y E K H K V Y A C E V T H Q G L S S P V T K S F N R G E C \* 233


Figure 7.

ATGGATGGAGCTGATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCGTCACACTGCAGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGC 120  
 M G W S C I I L F L V A T A T G V H S V Q L Q Q S G S E L K K P G A S V K V S C 40  
 AAGGCTTCTGGATACACCTTCACAAACTATGGAATGAACTGGGTGAAGCAGGCCCTGGACAAGGCTTAAATGGATGGCTGGATGAACACCTACACTGGAGAGCAACATATACTGAT 240  
 K A S G Y T F T N Y G M N W V K Q A P G Q G L K W M G W I N T Y T G E P T Y T D 80  
 GACTTCAAGGGACGGTTTGCCTTCTCCTTGGACACCTCTGTAGCACGGCATATCTCCAGATCAGCAGCCTAAAGGCTGAGGACATGCCGTGTTATTTCTGTGCAAGAGGGGGTTTCGGT 360  
 D F K G R F A F S L D T S V S T A Y L Q I S S L K A D D T A V Y F C A R G G F G 120  
 AGTAGCTACTGTGTAATCTGGGGCAAGGTCCTGGTCAACGCTCTCCTAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTTGGGGGC 480  
 S S Y W Y F D V W G Q G S L V T V S S A S T K G P S V F P L A P S S K S T S G G 160  
 ACAGCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGGGCCCTGACAGGGGGTGACACCTTCCCGGCTGTCTCAGTCTCCTCAGGA 600  
 T A A L G C L V K D Y F P P E P V T V S W N S G A L T S G V H T F P A V L Q S S G 200  
 CTCTACTCCCTCAGCAGCGTGGTACCGTCCAGCAGCTTGGGCAOCCAGACCTACATCTGCAAGTGAATCACAAGCCAGCAACCAAGGTGGACAAAGAGAGTTGAGCCCAAA 720  
 L Y S L S S V V T V P S S L G T Q T Y I C N V N H K P S N T K V D K R V E P K 240  
 TCTTGTGACAAAACCTCACACATGCCACCGTGGCCAGCAGCCTGAACTCTCTGGGGGACCGTCACTCTCTTCCCCCNAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAG 840  
 S C D K T H T C P C P A P E L L G G P S V F L F P P K P K D T L M I S R T P E 280  
 GTCAATGCCGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGTGACGTGGACGGGTGGAGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAACAGC 960  
 V T C V V V D V S H E D P E V K F N W Y V D G V E V H N A K T K P R E E Q Y N S 320  
 ACGTACCGTGTGGTCAGCGTCTCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAGCCCTCCAGCCCTCCAGAGAAACCAATCTCCAAA 1080  
 T Y R V V S V L T V L H Q D W L N G K E Y K C K V S N K A L P A P I E K T I S K 360  
 GCCAAAGGGCAGCCCGAGAACCAAGGTGTACACCTGCCCCCATCCCGGAGGAGATGACCAAGAACCAAGGTGACCTGCTGCTGCTCAAGGGCTTCTATCCAGCGACATCGCC 1200  
 A K G Q P R E P Q V Y T L P P S R E E M T K N Q V S L T C L V K G F Y P S D I A 400  
 GTGAGTGGGAGAGCAATGGGCGGAGAACAACTACAAGACCAGCCTCCCGTGTGGACTCCGAGGCTCTTCTCTCTATAGCAAGCTCACCGTGGACAAAGAGCAGGTGGCAG 1320  
 V E W E S N G Q P E N N Y K T T P P V L D S D G S F F L Y S K L T V D K S R W Q 440  
 CAGGGGAACGCTTCTCATGCTCCGTGATGATGAGGTCTGCACAACCACTACACGACAGAGCCTCTCCCTGTCTCCGGGTAAATGA 1410  
 Q G N V F S C S V M H E A L H N H Y T Q K S L S L S P G K \* 469

Figure 8.


**Chart-1. Structures of IMP-R4, IMP-R5 and IMP-R8**

In the structures, 'MCC' in IMP-R1 thru IMP-R6 is 4-(N-maleimidomethyl)-cyclohexane-1-carbonyl residue; and 'MMC' in IMP-R8 is maleimidomethylcarbonyl residue; 1-((*p*-CSNH)benzyl)DTPA is:



- IMP-R4:** MCC-Lys(MCC)-Lys(1-((*p*-CSNH)benzyl)DTPA)-D-Tyr-D-Lys(1-((*p*-CSNH)benzyl)DTPA)-OH
- IMP-R5:** MCC-Asp-D-Tyr-D-Lys(1-((*p*-CSNH)benzyl)DTPA)-OH
- IMP-R8:** MMC-Lys(MMC)-Asp-D-Tyr-D-Lys(1-((*p*-CSNH)benzyl)DTPA)-OH

**Figure 9**

**Figure 10**




Figure 11





Figure 12



**Figure 13**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
**WO 2003/074566 A3**

- (51) International Patent Classification<sup>7</sup>: **C07K 16/30**, G01N 33/53, 33/532
- (74) Agent: **W.P.THOMPSON & CO.**; Coopers Building, Church Street, Liverpool, L1 3AB (GB).
- (21) International Application Number: PCT/GB2003/000885
- (22) International Filing Date: 3 March 2003 (03.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/360,229 1 March 2002 (01.03.2002) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **IMMUNOMEDICS, INC.** [US/US]; 300 American Road, Morris Plains, NJ 07950 (US).
- (71) Applicant (*for BB, MG only*): **MCCALL, John, Douglas** [GB/GB]; 25 Haddon Drive, Pensby, Wirral, CH61 8TF (GB).
- (72) Inventors: **GOVINDAN, Serengulam**; 106 Passaic Avenue, Summit, NJ 07901 (US). **QU, Zhengxing**; 15 Sycamore Way, Warren, NJ 07059 (US). **HANSEN, Hans, J.**; 6014 Angler Drive, Picayune, MS 39466 (US). **GOLDENBERG, David, M.**; 330 Pleasant Valley Road, Mendham, NJ 07945 (US).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
4 March 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: RS7 ANTIBODIES

(57) Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.



WO 2003/074566 A3

# INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/GB 03/00885

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/30 G01N33/53 G01N33/532

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
|------------|---|--|
| X          | SHIH L B ET AL: "IN VITRO AND IN VIVO REACTIVITY OF AN INTERNALIZING ANTIBODY, RS7, WITH HUMAN BREAST CANCER" CANCER RESEARCH, vol. 55, no. 23, SUPPL, 1 December 1995 (1995-12-01), pages 5587S-5863S, XP000999121 ISSN: 0008-5472 | 1,2,15, 17-19, 26-31, 34,36, 37, 49-53, 56-59, 73, 79-82, 88-99, 105-124 |
| Y          | the whole document  | 3-14,16, 20-25, 32,33, 35, 38-51, 54,55, 60-124                          |
|            | ---   | ---  |
|            | -/--  |  |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 November 2003

Date of mailing of the international search report

11.12.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

## INTERNATIONAL SEARCH REPORT

Internationa Application No

PCT/GB 03/00885

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |
|------------|--|--|
| Y          | <p>QU Z ET AL: "Humanization of Immu31, an alpha-fetoprotein-specific antibody."<br/>           CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES OCT 1999, vol. 5, no. 10 Suppl, October 1999 (1999-10), pages 3095s-3100s, XP001154527<br/>           ISSN: 1078-0432<br/>           cited in the application<br/>           page 3096S, right-hand column, paragraph 2<br/>           -page 3097S, left-hand column, line 2</p> <p>---</p> | <p>3-11,40,<br/>           41,<br/>           49-51,<br/>           79-82,87</p>   |
| Y          | <p>WO 98 42378 A (GOLDENBERG DAVID M ;IMMUNOMEDICS INC (US))<br/>           1 October 1998 (1998-10-01)</p> <p>page 13, line 18 -page 29, line 2</p> <p>---</p>  | <p>16,<br/>           20-25,<br/>           32,33,<br/>           35,38,<br/>           54,55,<br/>           73,79-82</p>                         |
| Y          | <p>US 2002/006379 A1 (HANSEN HANS J ET AL)<br/>           17 January 2002 (2002-01-17)<br/>           claims 17-23</p> <p>---</p>  | <p>60-72</p>   |
| Y          | <p>DE 100 34 607 A (JUNG GUNDRAM)<br/>           7 February 2002 (2002-02-07)</p> <p>figure 1<br/>           paragraph '0014! - paragraph '0019!</p> <p>---</p>  | <p>12-14,<br/>           39-43,<br/>           49-51,<br/>           74-82,<br/>           87-93,<br/>           95-99,<br/>           105-124</p> |
| Y          | <p>SCHOONJANS R ET AL: "Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives"<br/>           JOURNAL OF IMMUNOLOGY,<br/>           vol. 165, no. 12,<br/>           15 December 2000 (2000-12-15), pages 7050-7057, XP002207879<br/>           ISSN: 0022-1767<br/>           figure 1</p> <p>---</p> <p>-/--</p>  | <p>44-48,<br/>           83-86,<br/>           94,<br/>           100-104</p>  |

## INTERNATIONAL SEARCH REPORT

Intern Application No  
PCT/GB 03/00885

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |
|------------|--|---|
| A          | LEUNG S O ET AL: "CHIMERIZATION OF LL2, A RAPIDLY INTERNALIZING ANTIBODY SPECIFIC FOR B CELL LYMPHOMA" HYBRIDOMA, vol. 13, no. 6, 1 December 1994 (1994-12-01), pages 469-476, XP000616008 ISSN: 0272-457X cited in the application abstract; figures 1,2<br>---                       | 12,13   |
| A          | WO 98 12227 A (DARVEAU ANDRE ;FRADET YVES (CA); DIAGNOCURE INC (CA)) 26 March 1998 (1998-03-26)<br><br>page 6, line 26 -page 7, line 2<br>---  | 44-48,<br>83-86,<br>94,<br>100-104                                  |
| A          | WO 00 69914 A (OXFORD BIOMEDICA LTD ;REURS ANNEKE (NL); BEIBOER SIGRID HERMA WILM) 23 November 2000 (2000-11-23)<br><br>page 25, line 31 -page 28, line 10<br>---  | 12-14,<br>39-43,<br>49-51,<br>74-82,<br>87-93,<br>95-99,<br>105-124 |
| P,X        | STEIN RHONA ET AL: "Therapy of a breast cancer xenograft using humanized RS7 labeled with residualizing iodine." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), pages 88-89, XP001154183 ISSN: 0197-016X abstract<br>----- | 1-8,15,<br>17-19,<br>52,53,<br>56-58,<br>80,99                      |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/00885

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 52-60, 62-71, 73-112, 121-124 are directed to a method of treatment of the human/animal body or to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-25, 28-38, 52-73 and part of 27, 49-51, 79-82, 88-92, 95, 97-99, 105-109, 111-123

Subject-matter relating to an antibody that binds to an EGP-1 glycoprotein and humanized derivatives thereof.

2. Claims: 26, 39-48, 74-78, 83-87, 93, 94, 96, 100-104, 110, 124 and part of 27, 49-51, 79-82, 88-92, 95, 97-99, 105-109, 111-123

Subject-matter relating to multivalent, multispecific antibodies and antibody fusion proteins comprising one or more antigen-binding sites having affinity to a EGP-1 glycoprotein.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 03/00885

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)  | Publication<br>date       |
|---|---------------------|-----------------------------|---------------------------|
| WO 9842378                                | A                   | 01-10-1998                  | AU 728325 B2 04-01-2001   |
|   |                     | AU 6761098 A 20-10-1998     |                           |
|   |                     | EP 0969866 A1 12-01-2000    |                           |
|   |                     | JP 2001518930 T 16-10-2001  |                           |
|   |                     | US 6183744 B1 06-02-2001    |                           |
|   |                     | WO 9842378 A1 01-10-1998    |                           |
|   |                     | US 6306393 B1 23-10-2001    |                           |
|   |                     | US 2003124058 A1 03-07-2003 |                           |
|   |                     | US 2002071807 A1 13-06-2002 |                           |
|   |                     | ZA 9802438 A 04-11-1998     |                           |
| US 2002006379                             | A1                  | 17-01-2002                  | WO 02082041 A2 17-10-2002 |
|   |                     | US 2003198595 A1 23-10-2003 |                           |
|   |                     | AU 760854 B2 22-05-2003     |                           |
|   |                     | AU 4579299 A 10-01-2000     |                           |
|   |                     | CA 2335364 A1 29-12-1999    |                           |
|   |                     | EP 1089766 A2 11-04-2001    |                           |
|   |                     | JP 2002518460 T 25-06-2002  |                           |
|   |                     | WO 9966951 A2 29-12-1999    |                           |
|   |                     | US 6228362 B1 08-05-2001    |                           |
| DE 10034607                               | A                   | 07-02-2002                  | DE 10034607 A1 07-02-2002 |
|   |                     | AU 7063701 A 05-02-2002     |                           |
|   |                     | CA 2416572 A1 31-01-2002    |                           |
|   |                     | WO 0208291 A2 31-01-2002    |                           |
|   |                     | EP 1303540 A2 23-04-2003    |                           |
| WO 9812227                                | A                   | 26-03-1998                  | AU 4373197 A 14-04-1998   |
|   |                     | WO 9812227 A1 26-03-1998    |                           |
| WO 0069914                                | A                   | 23-11-2000                  | AU 4935000 A 05-12-2000   |
|   |                     | WO 0069914 A2 23-11-2000    |                           |